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ABSTRACT 
Leukocyte-specific protein 1 (LSP1), an F-actin binding protein, is involved in neutro-
phil recruitment into peritoneum. Because mechanisms of excessive migration of activated neu-
trophils into inflamed lungs, credited with tissue damage, are not fully understood, we explored 
the hitherto unknown expression and role of LSP1 in neutrophil migration in a mouse model of 
acute lung inflammation. We induced acute lung inflammation through intranasal E. coli lipo-
polysacharide (LPS) (80μg) in wild-type 129/SVJ (WT) and LSP1 deficient (LSP1/) mice. WT 
(n=10) and LSP1
/ 
(n=11) mice showed significant neutrophilia and more neutrophils in bron-
cho-alveolar lavage (BAL) at 9 hour post-LPS challenge compared to respective saline-treated 
controls (WT=7; LSP1
/-
=10). LPS treatment induced more BAL neutrophils (P<0.001), 
myeloperoxidase concentrations and Gr-1
+
 neutrophils in lung tissues in WT mice compared to 
LSP1
/ 
mice. Lung myeloperoxidase and Gr-1
+
 (P<0.05) were higher in LPS-treated WT com-
pared to the LSP1
/ 
mice. Lung tissue and BAL fluid KC, MCP-1, MIP-1α and MIP-1β concen-
tration and vascular permeability were not different between LPS-treated WT and LSP1
/
 mice 
but TNF-α concentration was higher in LPS-treated WT mice. Hematoxylin and eosin staining 
showed more septal congestion in LPS-treated WT mice compared to LSP1
/ 
mice. LSP1 ex-
pression was increased in lungs from LPS-treated mice compared to saline control. The autop-
sied lungs from septic humans, compared to their respective controls, showed increased expres-
sion of LSP1. These data show that LSP1 expression is modulated in acute lung inflammation 
and that LSP1 deficiency reduces neutrophil migration into acute lung inflammation.
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1. INTRODUCTION 
In 1988, lymphocyte-specific gene 1 (LSP1) encoding 300-330 amino acid phosphopro-
tein of 47-60 kD molecular weight was recognized in pre-B cells, B cells, and concanavalin A-
stimulated murine thymocytes (1, 2). In humans, this protein, coded by the gene located at p15·5 
on chromosome 11, has 67% homology to the mouse gene (3, 4). Because the protein is ex-
pressed in monocytes, macrophages, neutrophils and endothelium, the name was changed to 
Leukocyte specific protein 1 (5-7). It is reported that LSP1 rs3817198T>C polymorphism was 
associated with an increased risk of developing breast cancer (8). Furthermore, interaction of this 
protein with C-type lectins could allow human immunodeficiency virus (HIV) to enter dendritic 
cells (9). The COOH- terminal of LSP1 is responsible for the association of LSP1 with the cyto-
skeleton, especially filamentous-actin (F-actin), in the filopodia, lamellipodia, ruffles, and the 
actin-rich cell cortex of neutrophils during chemotaxis in vitro (2, 10, 11). LSP1 is a major 
downstream substrate of p38 mitogen-activated protein kinase as well as protein kinase C. Taken 
together, this protein appears to have important roles in cell signaling and functions (7). 
Neutrophils are prominent players in acute lung inflammation, which accompanies 
many infectious and non-infectious lung diseases of animals and humans. For example, acute 
respiratory distress syndrome, one of the most serious forms of acute lung inflammation (ALI), 
causes 40% mortality in nearly 200,000 patients in the USA every year and results in significant 
healthcare costs (12, 13). The annual economic losses inflicted on animal industry in the United 
State of America and Canada by acute respiratory diseases of domestic animals caused by patho-
gens such as Mannheimia hemolytica, Streptococcus pneumonia, and Escherichia coli (E. coli) 
runs into billions of dollars (13-15). The most common signs of ALI include edema caused by an 
increase in permeability of the alveolar capillary wall, impaired blood oxygenation and exuber-
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ant migration of activated neutrophils into inflamed lungs (16, 17). Nevertheless, treatment for 
respiratory diseases of bacterial origin is becoming challenging because of emergence of antibi-
otic resistant bacteria, and side effects of prolonged medication such as high doses of cortico-
steroids (18), adrenal insufficiency, osteoporosis, brittle skin, vision and abnormal growth (19). 
Because of the ongoing mortality, morbidity and economic losses associated with acute lung in-
flammatory diseases, there is a need to understand the molecular mechanisms to develop better 
therapeutics to manage respiratory diseases.  
Leukocyte migration into an inflamed organ is one of the earliest signs and also a hall-
mark of ALI. The migration of activated leukocytes follows a molecular cascade that involves 
many surface adhesive proteins expressed on leukocytes and the endothelium (13). In addition to 
the adhesion, the leukocytes reconfigure their shape through modulation of their cytoskeleton to 
navigate the vascular barrier and the interstitium. There is evidence of increased polymerization 
of F-actin under the plasma membrane to induce shape changes in the leukocytes to facilitate 
their locomotion (13, 20). The activated leukocytes also release proteases and reactive oxygen 
species (ROS) to disrupt the barrier to migrate and also to increase vascular permeability (13, 
20). It is believed that while neutrophils play an important role in host defense including in the 
lung, the excessive migration of activated neutrophils causes significant tissue damage resulting 
in mortality and morbidity (20, 21). Therefore, we need to develop new molecular interventions 
to fine-tune the migration of neutrophils into inflamed lungs to balance their defensive functions 
against their deleterious actions. However, to achieve this goal, we need to develop a deeper and 
more precise understanding of the molecules that regulate their migration into inflamed lungs. 
There are data on the role of LSP1 in leukocytes, especially neutrophil recruitment in 
the vasculature of cremaster muscles, peritoneum, knee joint and skin (7, 22, 23). However, to 
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our knowledge, there are no such data on the expression of LSP1 in normal and inflamed lungs 
or on its role in the migration of leukocytes in acute inflamed lungs. Therefore, I hypothesized 
that LSP1 expression was altered in inflamed lungs and that LSP1
/
 inhibited acute lung in-
flammation in mice through inhibition of neutrophil migration. 
 
4 
 
2. LITERATURE REVIEW 
2.1. ACUTE LUNG INFLAMMATION 
2.1.1. Pernicious influences of acute lung inflammation on society 
In 1967, acute respiratory distress syndrome (ARDS), one of the most serious forms of 
acute lung injury, was identified as a lethal condition in adult (24). In children, the incidence of 
ALI is significant and there is a correlation between severity of arterial hypoxemia and high mor-
tality (25, 26). Approximately 40% of mortality that occurs in nearly 200,000 American patients 
every year is the result of ARDS (12, 13, 27). Additionally, the mortality of ARDS in human 
reaches to 34% in Australia (28) and 57.9% in Europe (29), representing significant perilous out-
comes of ALI. 
The annual economic losses inflicted on the animal industry in the United State of 
America and Canada by acute respiratory diseases of domestic animals runs into billions of dol-
lars (13-15). The economic cost of fatal pneumonia associated with Mannheimia haemolytica 
alone in beef cattle is reported to be in the range of billion dollars in Alberta, Canada (30). 
The acute lung injury manifests itself in lung edema caused by an increase in permea-
bility of the alveolar capillary wall and impaired blood oxygenation (13). Furthermore, bronchial 
and alveolar epithelial cells are also damaged (13, 20). No “gold standard” for diagnosing ALI 
has been demonstrated until now (31). In addition to high mortality, pulmonary, neuromuscular, 
cognitive and psychological dysfunctions are consequences of long term lung injury. Financial 
burden during and after this critical condition is incalculable (31). 
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2.1.2. Etiology of acute lung inflammation 
The most common cause of ALI and ARDS is bacterial and viral pneumonia (32, 33). 
In animal, many pathogens and their toxin induce acute pneumonia such as Actinobacillus pleu-
ropneumoniae in pigs, Rhodococcus equi in foals, a Gram-negative E. coli, Gram-positive Strep-
tococcus pneumoniae (pneumococcus, S. pneumoniae), severe acute respiratory syndrome 
(SARS) coronavirus and swine influenza virus(16, 17, 27, 34, 35). In pigs, Actinobacillus suis, 
Streptococcus suis and Haemophilus suis enter through inhalation and reside in the airways. En-
vironmental stressors such as air pollution, high temperature and humidity cause bacterial repli-
cation. These organisms express virulence molecules such as capsular molecules, fimbriae, out-
er-membrane protein that injure epithelial and endothelial cells to result in fibrinogen leakage 
and even mortality (36). 
There are data to show contributions of environmental and genetic factors to the ALI 
susceptibility and severity. Chronic alcohol abuse (37) and cigarette smoke exposure (38) in-
crease the risk of developing ALI. PPFIA1 gene encoding liprin alpha, a protein involved in cell 
adhesion, integrin expression, and cell-matrix interactions, is considered a potential ALI risk 
gene (39). FAS receptor (CD95) modulating apoptosis was also reported to associate with ALI 
susceptibility and risk of death (40). Drugs, burns, inhalation injury and pancreatitis are con-
cerned as potential risk factors for ALI (31). 
Intra-tracheal instillation of LPS, which is derived from Gram-negative bacterial cell 
wall, causes ALI, and is commonly used to model bacterial ALI. The LPS treatment alters the 
abilities of polymorphonuclear leukocytes to transit the pulmonary vasculature because of their 
increased stiffness and expression of adhesion molecules (20, 41). Macrophages/monocytes 
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stimulated by LPS produce early pro-inflammatory cytokines such as tumor necrosis factor α 
(TNF-α), interleukin-1 (IL-1), IL-6 and interferon-γ (IFN-γ) to protect against infection. Moreo-
ver, these leukocytes can cause late release of pro-inflammatory cytokines, for example high 
mobility group box 1 (HMGB1) contributing to the tissue injury repair at the later stage (42-44). 
2.1.3. Mechanisms of acute lung inflammation 
The acute lung inflammatory mechanisms are incompletely understood and are depend-
ent on the initiating causes of the lung injury. The primary mechanism of lung inflammation in-
volves the activation of alveolar macrophages to produce cytokines after pathogen has invaded 
the lung. In the airway, alveolar macrophages release cytokines (IL-1, IL-6, IL-8, IL-10) and 
TNF-α to stimulate chemotaxis and activate neutrophils (13). Stimulated leukocytes and chemo-
kines, a kind of cytokine, are proven to have an important function in ARDS pathogenesis (45). 
Moreover, there is presence of anti-inflammatory mediators including IL-1 receptor antagonist, 
soluble TNF receptor, auto-antibodies against IL-8, and cytokines such as IL-10 and IL-11 in the 
alveolar milieu (13, 20). However, an imbalance between the pro-inflammatory and anti-
inflammatory cytokines is believed to occur in ALI (46). 
Neutrophils are the first immune cells to migrate into inflamed organs and their migra-
tion is one of the histological hallmarks of acute lung inflammation. These leukocytes play an 
important role in host defense, especially in fighting bacteria, which induce lung inflammation 
(20, 21). Neutrophils migrate through capillary wall into the interstitium and finally into the al-
veoli. Activated neutrophils release cytotoxic chemicals such as proteases, ROS (47), leukotri-
enes, pro-inflammatory cytokines, platelet-activating factor (PAF), and procoagulant molecules, 
which lead to an injury of endothelium and formation of lung edema (13, 20). ROS and molecu-
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lar interactions such as TLR4-TRIF-TRAF6 signaling (Toll-like receptors 4 -Toll-like receptor 
adaptor molecule - TNF receptor-associated factor 6) relate to important pathways in controlling 
ALI severity (48, 49). The migration of neutrophils can cause protein-rich hyaline membranes 
and protein-rich edema in the air space because of protein leakage from pulmonary vasculature 
into interstitium of the lung through disruption of endothelial barrier, resulting in high morbidity 
and mortality (50). In addition, activated platelets are believed to induce formation of neutrophil 
extracellular trap (NETs). NETs detected in the lungs and plasma of human transfusion-related 
acute lung injury (TRALI) may contribute to lung endothelial injury (51). Moreover, antimicro-
bial products in NETs and histones can injure endothelium and alveolar (52). The events of neu-
trophil migration and edema formation are regarded as cardinal pathophysiologic events in ALI 
(32, 53). 
2.2. NEUTROPHILS 
2.2.1. Neutrophil introduction 
Neutrophils, polymorphonuclear granulocytes, constitute 60-75% of circulating leukocytes 
in most carnivores. These leukocytes were first described as cells aggregating around an injury 
site by Elie Metchnikoff [88]. Bone marrow produces 5-10x10
10
 neutrophils per day to maintain 
equilibrium. The number of mature neutrophils in bone marrow is ten times greater than in circulato-
ry system (54). Ten-fold increase of neutrophil quantity may occur during bacterial infection (55). 
The most important abilities of neutrophils are their immigration capability, killing and inhibit-
ing microbial growth (56). 
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2.2.2. Neutrophil activation 
Neutrophils are motile cells that are activated by pro-inflammatory cytokines, LPS, and 
other agents. The active stage is recognized at the inflammatory site. Neutrophil activation is also 
induced by pathogens or their components such as pathogen-derived formylated peptides (57). 
Activated neutrophils, which are recruited from the blood flow to injured tissues, are the primary 
component of innate immune response to pathogens. In general, after being stimulated by bacte-
rial products such as LPS, endothelium exhibits P-selectin (CD62P) on its cell surface, which is 
basically a glycoprotein stored in cytoplasmic granules. P-selectin attaches to L-selectin 
(CD62L) on activated neutrophil surface to slow down neutrophil speed in small venules. After 
that, endothelium releases PAF to stimulate expression of adhesive protein named leukocyte 
function-associated antigen-1 (LFA-1, CD11a/CD18, integrin) on neutrophils. A firm adhesion 
will occur when LFA-1 of neutrophils binds an intercellular adhesion molecule-1 (ICAM-1, 
CD54) on endothelium. Neutrophils stopped in the blood vessels releases elastase to eliminate an 
anti-adhesive protein (CD43, leukosialin) on neutrophil surface for stronger binding with endo-
thelium (58). 
After being triggered by IL-1, IL-23, TNF-α, endothelium shows E-selectin adhesion 
molecule (CD62E), and secretes chemokine IL-8 (CXCL-8) to solicit more neutrophils (54). 
TNF-α also triggers the endothelium to produce IL-1 causing vasodilation, procoagulant activity, 
thrombosis, adhesive and chemotactic molecules. TNF-α also attracts more neutrophils. Addi-
tionally, when LFA-1 binds ICAM-1, neutrophils release CXCL1, 2, 3, 8 and cause protein leak-
age due to endothelial contraction and intercellular junction disruption. About one-fifth of neu-
trophils emigrate through endothelium, remaining leave venules through endothelial junctions. 
Neutrophils release protease to enter basement membrane (58). 
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Upon activation, neutrophils secrete pro-inflammatory cytokines/chemokines such as 
IL-1α, IL-1β, IL-1RA, TNF-α, IL-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), and 
transforming growth factor-β (TGF-β), which can promote inflammation and augment anti-
microbial function of host cells at the potential infected area (58, 59). Prostaglandins and leuco-
trienes were demonstrated to be synthesized by activated neutrophils in driving rheumatoid 
arthritis (60). Activated neutrophils also secrete superoxide anion (O
2-
) generating ROS such as 
hydrogen peroxide (H2O2), hydroxyl radical (OH
-
) and hypochlorous acid (HOCl) to kill mi-
crobes (57). Neutrophils and their cytokines are also implicated in chronic inflammation and the 
asthma (61) in addition to acute inflammatory responses. Inhibition of neutrophil derived cyto-
kines can be a potentially useful therapy for inflammation (52, 61, 62). 
2.2.3. Microbe clearance by neutrophils 
In contrast to macrophages, neutrophils assault and eat pathogen faster but they don’t 
have capability to prolong or repeat phagocytosis. Within 20 seconds, neutrophils grasp an opso-
nized particle. There are 5 main stages of phagocytosis including activation, chemotaxis, adher-
ence, ingestion, and destruction. After being stimulated by TNF-α, CXCL8 or C5a, and through 
integrin ligation, neutrophils produce elastase, defensins and oxidants (58). 
In innate immune response, neutrophils have CD35, named complement receptor-1 
(CR1), which binds complement component C3b coating microbes. Additionally, there are many 
pattern-recognition receptors (PRRs) covering phagocytic cells, which are ligands on bacteria 
surface. Neutrophils can recognize and adhere to bacteria directly through their mannose recep-
tors or integrins (58). 
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Activated neutrophils create an extracellular fiber network to catch bacteria called 
NETs, an early event of cell death, in the inflammatory areas. NETs are decondensed nuclear 
DNA strands coated by antimicrobial proteins consisting of histones and granule component, for 
example, from azurophilic primary granules (elastase, myeloperoxidase, cathepsin G), specific 
secondary granules (lactoferrin) and tertiary granuale (gelatinase). Therefore, NETs have im-
portant functions as a physical defence in preventing bacterial spread and suppress virulence fac-
tors. They can kill organisms before engulfing them but have deleterious impacts on the host tis-
sue (58, 63). 
There are two ways to demolish ingested organism: by potent oxidants through “respir-
atory burst” procedure or involvement of lytic enzymes and antimicrobial peptides from intracel-
lular granules of neutrophils. Another explanation for neutrophil killing microbes is the function 
of nicotinamide adenine dinucleotide phosphate oxidase (NOX) in pumping electron into phago-
cytic vacuole. The compensating ion movement will make a condition in the vacuole suitable 
through lowring of pH for activation of enzymes to kill and to digest organism (56). 
In the lytic enzyme phagocytic pathway, neutrophil granules or lysosomes move toward 
and fuse with the ingested pathogen, generating phagosome to form phagolysosomes. Neutrophil 
microbicidal products such as lysosomal enzymes, ROS, and nitric oxide will kill organism (58, 
64). Lysosomal enzymes including elastase, cathepsin G, lysozymes, proteases, acid hydrolases 
and myeloperoxidase are produced and aggregate in phagosomes to digest bacterial wall and de-
stroy most microbes (58). Lactoferrin binds redoxiactive metal such as iron to minimize OH 
formation and deprive this nutrient of bacterial development. These products can injure host tis-
sue concomitantly when going out extracellular environment although neutrophils have glutathi-
one to impair oxidant toxic and moderate the damage (56). 
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2.3. NEUTROPHIL MIGRATION INTO INFLAMED LUNGS 
2.3.1. Adhesion molecules 
In fact, the mechanisms of neutrophil immigration from the circulatory system to in-
flammatory tissues in the lung are highly complex and poorly understood (6). Many proteins in 
the families of selectins, integrins and immunoglobulin superfamily play roles in neutrophil in-
teractions with the endothelium. It is reported that selectins expressed on neutrophils lead to their 
rolling on the endothelium. Selectins, which refer to a group of transmembrane molecules con-
sisting of L-selectin, E-selectin, P-selectin and P-selectin glycoprotein ligand (PSGL1), have a 
varied expression on cells. L-selectin is expressed on leukocytes and E-selectin expression is on 
inflammatory endothelium. Both inflamed endothelium and platelets express P-selectin (CD62P) 
whereas PSGL1 is found in leukocytes and endothelium (65, 66). Nevertheless, selectins have 
some functions in neutrophil recruitment in pneumonia. Some scientists demonstrated that lung 
inflammation induced with intravenous cobra venom factor (CVF) or LPS administration 
showed increased P-selectin expression on lung vascular endothelium to promote neutrophil mi-
gration (67). Furthermore, P- selectin derived from platelets possibly plays a more important role 
in neutrophil sequestration than that from endothelium of murine. Platelets activation is investi-
gated as the reason behind the ICAM-1 expression in endothelium and an increase of neutrophil 
adhesive ability. The level of neutrophil migration, permeability, and prolonged survival de-
creased when the aggregation of platelets was prevented (68). 
Next, integrins and chemokines mediate firm adhesion of neutrophils to activated endo-
thelium. The integrins are membrane-linked proteins that adjust adhesion of cells by interaction 
with adhesion molecules such as ICAM-1, ICAM-2 and vascular cell adhesion molecule 1 
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(VCAM-1) (20). Some researchers illustrated that β2-integrins generally mediated neutrophil 
adhesion to migrate across the pulmonary vascular endothelial barrier upon the interaction of 
CD11/CD18 β2-integrins on polymorphonuclear leukocytes with their counter receptor, named 
ICAM-1, on the surface of vascular endothelial cells. It is concluded that preventing β2-integrins 
on activated endothelium can arrest PMNs activation and migration responses (69). However, 
neutrophil’s migration through pulmonary microvascular endothelium varies depending on path-
ogens. ICAM1, VCAM1 and E-selectin up-regulation did not affect neutrophil migration in the 
presence of LPS, E. coli, S. aureus and S. pneumoniae.  Blocking ICAM1, adhesion molecule on 
endothelium, did not down-regulate neutrophil migrating to LPS, E. coli, S. aureus and S. pneu-
monia (14). Neutrophil adhesion in response to E. coli, S. pneumoniae, S. aureus and LPS was 
known to occur through β2-integrins dependent pathway (70), (14). 
In contrast, data also show that a β2-integrin-independent pathway was observed in 
neutrophils migration in pneumonia induced with S. aureus (71) and S. pneumonia (70). CD18 
inhibition did not significantly down-regulate neutrophil immigration to intrapulmonary and S. 
aureus clearance in rabbit model (71). In rat model, the expression of integrin subunits alpha-v 
and beta-3 in acute lung inflammation on neutrophils and endothelium following intratracheal 
challenge with E. coli was lower than S. pneumonia challenging. However, both bacteria en-
hance similar levels of neutrophil migration into lungs (72). 
2.3.2. Chemokines/cytokines 
Many chemokines, particularly IL-8, and CXCL5 (named epithelial neutrophil-
activating protein 78 (ENA78)) produced by alveolar macrophages increase neutrophil infiltra-
tion (45). In rodent, CXCL1 (known as keratinocyte-derived chemokine (KC) or cytokine-
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induced neutrophil chemoattractant (CINC)) and CXCL2 (known as macrophage inflammatory 
protein-2 (MIP-2)) are significantly associated with neutrophil migration (73). Monocyte chemo-
attractant protein 1 (MCP1, named as CCL2 or MCAF), a chemoattractant for monocytes, and its 
hematopoietic cell receptor CC chemokine receptor 2 (CCR2) can contribute to set up an effi-
cient chemotactic gradient for neutrophils in lung inflammatory disorders (45, 74). 
IL8, MCP1, IL6, GRO-α and RANTES but not TNF-α were produced in significantly 
higher amounts after E. coli, S. aureu and S. pneumonia stimulation and highest following LPS 
treatment compared to unstimulated control in neutrophil-endothelium interaction in vitro. In 
contrast, E. coli stimulates neutrophil migration 10 times higher than purified LPS at the equiva-
lent LPS content. It is explained that intact bacteria have other constituent molecules, which acti-
vate neutrophils and the endothelium (14). 
2.3.3. Configuration change 
After tethering and rolling on the endothelium, the neutrophils change their configura-
tion as a requirement to move from small pulmonary capillaries to the interstitium. Then they 
enter the airway via alveoli (75). Neutrophil cytoskeleton is also altered by inflammatory stimuli 
through activation of 7-transmembrane-spanning G-protein linked receptors (76). 
Endothelial cytoskeleton, a complex network of actin microfilaments, microtubules, 
and intermediate filaments, contributes to shape change and transduce signals within and be-
tween endothelial cells. These components have important functions in controlling endothelial 
cell contractile forces and cell-matrix tethering forces (50). Actin cytoskeleton reorganization, 
orchestrated from extracellular signaling cascades, is an important event to allow neutrophil mi-
gration (77). 
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Previous studies demonstrated that ICAM-1 cross-linking activated p38 mitogen-
activated protein kinase (p38MAPK) phosphorylation, which is necessary for cytoskeletal re-
modeling in endothelial cells. Inhibition of p38MAPK reduced neutrophil paracellular migration 
(78). Neutrophil adherence was also observed to induce p38MAPK phosphorylation in the cen-
tral region of the endothelial cells after 2-6 minutes. p38MAPK isoforms, particularly MAPK 
kinase 3 and MAPK kinase 6 were identified as a requirement for cytoskeletal changes, conse-
quently enhance neutrophil migration toward endothelial cell junctions (79). 
Moreover, after intravascular inflammatory mediators triggered neutrophils in vivo, F-
actin from the central site redistributed quickly to the sub-membrane cytoplasm periphery and to 
the microvilli of neutrophils. Besides that, the increase of F-actin polymerization in cytoplasm 
perimeter can change the biomechanical properties of neutrophils. These factors caused not only 
a rise in stiffness and viscosity level but also a decline in the deformable ability of neutrophils, 
which are probably the reasons for neutrophil sequestration throughout inflammatory develop-
ment (76). The abnormal F-actin reconstitution affects neutrophil migration and extravasation 
from the vasculature into interstitial tissues (77). 
In general, the recruitment of neutrophils into the lung is unique because of the diame-
ter and tortuous nature of capillaries and the migration across the capillaries but not venules. The 
diameter of capillaries is such that neutrophils cannot flow through and need longer transit time 
to pass through pulmonary vasculature (75, 76, 80, 81). Because of such distinctive features and 
technical challenges in direct observation of neutrophil migration across the alveolar septum, the 
mechanisms of neutrophils recruitment in inflamed lung remain poorly understood. Therefore, 
there is a pressing need to develop a deeper and more precise understanding of the molecules that 
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regulate neutrophil migration into inflamed lungs to balance their defensive functions against 
their deleterious actions. 
2.4. NEUTROPHIL INTEGRATION WITH OTHER FACTORS IN ACUTE LUNG 
INFLAMMATION 
Most neutrophils have a short life-span (82). Their circulating half life in blood is 
around 6-8 hour while they stay in tissue about two or more days and die by apoptosis (54). In-
flammatory stimulants such as oxidants trigger neutrophil apoptosis (82, 83). 
After invading bacteria are killed by neutrophil products, which also damage the tis-
sues, the damaged tissue starts the process of repair through molecules such as resolvin E1 and 
protectin D1, and polyunsaturated fatty acid-derived lipids produced by endothelium. These 
molecules stimulate more macrophage infiltration, engulfment and digestion of apoptotic neutro-
phils. Consequently, macrophages inhibit tissue damage from neutrophil products such as en-
zymes and ROS through uptake of necrosed and apoptotic neutrophils. Macrophage interacts 
with neutrophils through many proteins including CD31 and integrin αvβ3. Macrophage endo-
some can also store, utilize and degrade enzymic content from neutrophil granules to restrict 
pathogen growth and have capability to repeat phagocytosis (58, 84, 85). 
Apoptotic neutrophil can also release annexin I and other peptide derivatives, known as 
pro-phagocytic factors to stimulate macrophages to phagocytose them. Apoptotic cells stimulate 
M2 macrophage to release IL-10 and TGF-β to prepare for phagocytosis. These cytokines and 
PAF have functions in resolution of inflammation, wound repair, and restoration of tissue home-
ostasis. Additionally, apoptotic cells release lactoferrin to inhibit more granulocyte immigration 
(86).The neutrophil-macrophage cooperation also induces many aspect of innate immunity. Co-
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operating with neutrophils, macrophages infiltrate to inflamed site to remove invaders or foreign 
particles from circular and respiratory system (87). Simultaneously, pathogen-associated molecu-
lar patterns (PAMPs), for instant LPS, bind Toll-like receptors (TLRs) on the surface of myeloid 
stem cells. These stem cells will be activated and produce more neutrophils (58). 
2.5. LEUKOCYTE-SPECIFIC PROTEIN 1 (LSP1) 
2.5.1. LSP1 introduction 
In 1988, LSP-1 gene encoding a 300-330 amino acid phosphoprotein named lympho-
cyte specific protein 1 was identified by Jongstra-Bilen and colleagues. This protein was recog-
nized in pre-B cells, B cells, concanavalin A-stimulated murine thymocytes, helper and cytotoxic 
T cell lines. A Ca
2+ 
dependent feature of normal T cell development is related to LSP1 (1, 2, 4, 
88, 89). However, T and B lymphocytes grow normally in mice lacking LSP1 (11). Because the 
protein was recognized in monocytes, macrophages, neutrophils and endothelium, the name was 
changed to leukocyte specific protein 1 in 1999.The LSP1 molecular weight varies from 47-60 
kD (1). Western blots showed that the LSP1 protein was expressed as a 52 kD band with both 
NH2-terminal and COOH-terminal domain in leukocytes and endothelial cells (4, 7). 
This protein is a major downstream substrate of p38MAPK, mitogen-activated protein 
kinase-activated protein kinase 2 (MAPKAPK2) as well as protein kinase C (90). Inhibiting 
p38MAPK by SB203580 will restrict endothelial LSP1phosphorylation compared to without 
p38MAPK inhibition under the similar conditions of neutrophil adherence (91). Moreover, aspi-
rin-triggered 15-epimers of lipoxin, known as anti-inflammatory agents, can reduce p38MAPK 
and LSP1 activation, leads to blocking neutrophil chemotaxis, influx and other pro-inflammatory 
responses (92). It is reported that p38MAPK inhibition can prevent cell polarization and actin 
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bundle formation under PAF stimulation in neutrophils. However, MAPKKAPK-2 prevention or 
intracellular LSP1 neutralization solely reduces actin bundle formation. It suggests that LSP1 is a 
substrate in one of p38MAPK signaling pathways in managing cell motility (93). 
2.5.2. LSP1 gene 
In humans, LSP1, named as WP34, pp52 or leufactin, is coded by the gene located at 
p15·5 on chromosome 11. It has 67% homology to the mouse gene, which is located on distal 
chromosome 7 (3, 4), (94). Although both human and mouse genes have similar pattern of ex-
pression, human genome has some fragments corresponding with some LSP1 isoforms (4). 
LSP1 transcription in leukocytes and fibroblasts is controlled by a 549 bp tissue-
specific promoter. This area also contains an activated silencer gene, called pp52 negative regu-
latory element (NRE), localizing to an 89 bp DNA segment between −324 and −235 bp area of 
promoter. However, leukocyte gene has pp52 anti-NRE region, serving as an anti-silencer gene. 
This anti-silencer gene is a 33 bp segment between −383 and −350 bp area of promoter. There-
fore, it allows LSP1 gene to be transcripted in leukocytes. In contrast, fibroblasts do not have the 
anti-silencer gene so the silencer gene is activated mostly, leading to inhibit LSP1 expression 
(95). 
2.5.3. Binding sites of LSP1 
In LSP1 sequence, the acidic N-terminal domain is for Ca
2+
 binding. In human LSP1, 
there is only one Ca
2+
 binding domain, which is different from two Ca
2+
 binding sites in mouse 
(4, 96). The association of LSP1 with the cytoskeleton, especially F-actin in mouse is mediated 
through basic COOH-terminal site (10) which is also the phosphorylation area (11, 90). 
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In 2000, Zhang and colleagues described that LSP1 interacts with F-actin through elec-
trostatic affinity. The binding sites of LSP1 with F-actin are in three main regions of amino ac-
ids: 181-245, 246-295, and 306-339 which correspond to caldesmon I (CI), caldesmon II (CII), 
and two villin headpiece homologous regions (VI and VII)(97). The site within the residues 231–
330 binds LSP1 tightly with F-actin (6). In 2003, Wong and colleagues confirmed that the resi-
due from 300-330 was the binding site of LSP1 with cytoskeleton. The binding of LSP1 and F-
actin can be restricted by changing the basic residues of domain corresponding to VII domain 
(2). 
LSP1 phosphorylation induced after formylmethionyl-leucyl-phenylalanine (fMLP) 
treatment was identified at serine 204 and 252 in the basic C-terminal F-actin binding site in hu-
man neutrophils and corresponding position in mouse LSP1 is 195 and 243serine (11, 90). LSP1 
phosphorylation residues overlap or are just behind the F-actin binding domains, the phosphory-
lation overlaps or occurs just after F-actin polarization. Some phosphorylated LSP1 (pLSP1) can 
also be found at trailing edge of neutrophils. Moreover, the affinity of LSP1 and F-actin can be 
influenced by phosphorylation of LSP1 since the CII domain binding area is right after the major 
phosphorylation site (serine 243) (11, 98).  
2.5.4. LSP1 expression 
There are reports that LSP1 is expressed on endothelium, monocytes, macrophages, 
neutrophils, B-cells, and T-cells including Thyl+ thymocytes (5-7). Early on, LSP1 mRNA or 
protein were not identified in granulocyte or non-differentiated HL60 cell lines(4). Later on, the 
60 kD LSP1 expression was localized in HL60 and U937 cell lines with immunohistochemistry. 
Additionally, flow cytometry results show that LSP1 is recognized in CD19-positive circulating 
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B cells of blood but missing in pre-B cells and the CEM T-ALL cells (peripheral blood buffy 
coat of a child CEM with T acute lymphoblastic leukemia who had originally presented with 
lymphosarcoma) (1). There are data that LSP1 is not expressed in myeloid cells and other hema-
topoietic lineages such as erythrocytes (K562), mast cells, or megakaryocytes (HEL cell line) (1, 
99). This protein is also not found on non-lymphoid cell lines or normal mouse tissues such as 
brain, lung, liver, skeletal muscle, kidney or testis (88, 100). 
LSP1 protein was strongly expressed in cytoplasm of circulating blood monocytes, 
lymphocytes, and neutrophils. The LSP1 expression is noticed only in a few cells in the thymic 
cortex, splenic red pulp, lung, and liver (1). In thymus, double-immunofluorescence labeling 
shows that this protein is expressed at a higher level in medullary thymocytes, which are mature, 
compared to cortical thymocytes. This suggests that LSP1 may have an important function in the 
development of T-cell. In liver, LSP1 is not found in Kupffer cells by immuno-alkaline phospha-
tase immuno-cytochemistry. In tonsils, LSP1 is present in germinal centres, mantle zones, and 
interfollicular areas. LSP1 is expressed in plasma B cells, Langerhans’ cells and dendritic cells in 
tonsilar T-cell areas but not in macrophages in the germinal centers and epithelium. By flow cy-
tometry, LSP1 is observed in some CD3-positive T cells.  In spleen, this technique also shows 
LSP1 in a lymphoid area but absent from the sinusoidal lining cells or red pulp macrophages. In 
lung, some alveolar macrophages express LSP1. It is believed that LSP1 expression is different 
in various stages of differentiation of macrophages (1, 100). Nevertheless, there have been lim-
ited studies on the expression of LSP1 in the lung and also specific cell types in the lung.  
LSP1 was observed in the nucleus and cytoplasm of cultured mouse microvascular en-
dothelial cells and human umbilical vein endothelial cells (HUVECs) in vitro with immunofluo-
rescence (7). Biochemical techniques showed that LSP1 could spread from nucleus to cytoskele-
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ton in HUVECs. By western blot, LSP1 was actually observed more strongly in the cytosol and 
nucleus than in the membrane and cytoskeleton. After activation by TNF-α, LSP1 levels in cyto-
skeleton increased but not in the nucleus and cytosol. In contrast, after leptomycine B admin-
istration, a substance inhibiting export from nucleus, level of LSP1 expression rose in nucleus 
but not in cytoskeleton. It suggests that LSP1movement from nucleus to cytoskeleton has an im-
portant function in managing the cytoskeleton, which affects the cell shape (101). 
Proteomic analysis on human neutrophil granules revealed LSP1 in gelatinase granules 
and specific granules associating actin cytoskeleton activity and phagosomes (102). Besides that, 
LSP1 was found to be associated with F-actin in the filopodia, lamellipodia, ruffles, and the ac-
tin-rich cell cortex of neutrophils during chemotaxis in vitro (2, 10, 11). This protein was also 
observed in many cases of cancer in the lymphatic cells, bone marrow and classical Hodgkin’s 
disease (1). 
2.5.5. LSP1 functions 
LSP1 plays an important role in leukocyte chemotaxis into inflamed organs (23). In 
other words, neutrophil recruitment through postcapillary venules of LSP1
/
 mice is restricted 
even when activated by various cytokines (TNF-α and IL-1β) and KC in vivo. In particular, en-
dothelial LSP1 has a significant role in transendothelial migration of neutrophils. Moreover, in-
travital microscopy has shown a role for LSP1 in neutrophil migration induced by both KC and 
MIP2 in mouse cremaster muscle (22). Additionally, LSP1 has a function in histamine-induced 
increased permeability in poscapillary venules likely through its interactions with endothelial 
cytoskeleton (7).
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Recent data shows that LSP1 has also functions in dome formulation of endothelium in 
vivo. Whole-mount staining of cremaster muscle tissue or 2-photon microscopy showed a dou-
ble-fold increase in the quantity of domes in wild-type mice compared to LSP1
/ 
mice after 
TNF-α or IL-1β administration. Moreover, transmission electron microscopy technique illustrat-
ed that endothelial domes completely enveloped neutrophils in wild-type but not in LSP1
/
 mice 
(101).
 
Additionally, LSP1 affected shape, flux and superoxide production of neutrophils (10). 
LSP1
/ 
neutrophils cannot generate actin bundles during chemotaxis, as indicated by confocal 
microscopy data. After phorbol12-myristate 13-acetate (PMA) treatment, superoxide anion was 
produced by LSP1
/
 peritoneal neutrophils more than wild-type neutrophils. However, lack of 
LSP1 did not affect superoxide production level after KC stimulation to peritoneal neutrophils. 
The authors also concluded that LSP1 could reorganize the cytoskeleton of vermin neutrophil 
related to chemokine KC stimulation in vitro.
 
Nevertheless, an opposite function of LSP1 was explained by a β2 integrin-dependent 
pathway. LSP1 modulates the Mac-1 (CD11b/CD18) function in binding to fibrinogen and 
ICAM-1 ligand, which regulates neutrophil chemotaxis. LSP1 deficiency causes neutrophil ad-
hesion, polarization, immigration, and fibrosis in inflammation in skin and knee joints. These 
resulted in accelerated injury healing (23, 103, 104). 
Endothelial LSP1 was phosphorylated when neutrophils adhered to the endothelium 
and that phosphorylation allowed neutrophil to adhere stronger. Neutrophil adhesion and endo-
thelial LSP1 phosphorylation depended on neutrophil β2 integrins/CD18 and endothelial ICAM-
1. β2 integrin blockage reduced lung, heart, and murine SVEC4-10EE2 endothelial phosphoryla-
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tion and MIP2-stimulated neutrophil adhesion. Results were the same when ICAM1 was blocked 
before endothelium was administered by TNF-α. Phosphorylated endothelial LSP1 was increased 
by cross-linking ICAM1 or ICAM1-mediated adhesion (91). These data show that LSP1 cooper-
ates with beta2-integrins and ICAM-1 in neutrophil adhesion to the endothelium. 
LSP1 is involved in increasing motility, microfilamentous cytoskeletal abnormalities, 
and imperfection in actin polymerization dynamic in neutrophil actin dysfunction (NAD), ob-
served in human immunodeficiency syndrome (105). Interaction of LSP1 with C-type lectins can 
also allow HIV to enter dendritic cells (9). In 2009, Anand et al. reported that siRNA LSP1 
down-regulated dendritic cell migration by 50% compared to non-target siRNA treated dendritic 
cells and LSP1 redistributed in cytoplasmic projections and associated obviously with actin. 
Normal dendritic cells can inhibit HIV-1 transfer to lymphoid T cells compared with siRNAs 
treated LSP1 deficient dendritic cells in human. Similarly, LSP1
/
 bone marrow dendritic cells 
also enhanced HIV-1 transfection to human T-cell line. It is indicated that LSP1 regulated den-
dritic cell migration in response to HIV-1 gp120 (106). It is reported that different hairy cell leu-
kemia morphology can be associated with LSP1 expression (107). LSP1 may also have a role 
ononcogenesis (1). In fact, results by meta-analysis showed that LSP1 rs3817198T>C polymor-
phism was associated with an increased risk of developing breast cancer (8). 
It was known that CD64 (FcγRIa), a membrane glycoprotein, binds strongly with IgG 
antibody then interacts with γ chain having immuno receptor tyrosine-based activation motif to 
stimulate cells (108). This receptor can be found on the surface of monocytes, macrophages, and 
activated neutrophils. CD64 enhances phagocytosis, endocytosis, and inflammatory production 
(109, 110). Some scientists used mutant form of FcγRIa lacking the cytoplasmic domain tail in 
murine macrophages to examine the relationship of this receptor in modulation of some gene ex-
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pression including LSP1. After macrophages were incubated with anti-FcγRIamAbF (ab’) to 
achieve receptor-specific cross-linking, LSP1 gene and mRNA expression level was greater in 
macrophage transfected with cDNA-encoding human FcγRIa (CD64) than mutant macrophages. 
It was indicated that LSP1 is involved cytoplasmic domain of FcγRI a (CD64) α-chain modulat-
ing the transcriptional activity induced by receptor-specific engagement in macrophages. In other 
words, LSP1 is probably related to some macrophage functions consisting of phagocytosis, en-
docytosis, and intracellular trafficking of receptor-Ag complexes (111). 
LSP1 can induce anti-IgM mediated apoptosis by regulating a Ca
2+
 dependent pathway 
in WEHI-231 cell and normal immature B cells. Apoptosis increase can be a result of membrane 
immunoglobin M regulated by LSP1 through residue 179 and 330 (112). It was explained that 
this protein can bind PKC-beta I and inhibit anti-IgM-induced PKC-beta I translocation (113). 
However, Laurent Sabbagh and colleagues reported that LSP1 was involved in T cell 
survival through 4-1BB signaling, a type 2 trans-membrane glycoprotein belonging to the TNF 
death receptor. Ligand 4-1BB, named CD137, which binds to TNF receptor-associated factor 1 
(TRAF1), is important for CD8 T cell survival. It is suggested that LSP1 is a requirement down-
stream of 4-1BB to regulate proapoptotic Bcl-2 interacting mediator of cell death (Bim) content. 
LSP1 binds N-domain of TRAF1 of CD8+ T cells. LSP1-TRAF1 cooperation also activates ex-
tracellular-signal-regulated kinases (ERK) pathway to increase survival of T cells (114). 
Taken together, LSP1 plays an important role in neutrophil chemotaxis, recruitment in-
to inflammatory organs. To our knowledge, while significant data are available on the role of 
LSP1 in leukocytes, especially neutrophil recruitment in cremaster muscles, peritoneum, knee 
joint and skin (7, 22, 23), there are very few data on the expression and function of LSP1 in acute 
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lung inflammation. Therefore, I proposed a series of studies to understand the expression and 
function of LSP1 in a mouse model of LPS-induced acute lung inflammation. 
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3. HYPOTHESES and RATIONALE 
It is reported that alveolar macrophages depending on the stage of differential express 
LSP1 (1). Nevertheless, there have been limited studies on the expression of LSP1 in the lungs. 
Because of the role of inter-cellular communication in organ physiology, it is important to under-
stand cell-specific expression of a protein to elucidate its functions. Therefore, I hypothesized 
that (1) LSP1 was expressed in mouse and human lungs and (2) its expression was increased in 
inflamed lungs. (3) Additionally, LSP1 had an important role in neutrophil recruitment during 
acute lung inflammation. 
Moreover, the role of LSP1 in neutrophils chemotaxis and migration has been exam-
ined in organs other than the lung (23). Neutrophil recruitment through postcapillary venules of 
LSP1
/
 mice is attenuated even when activated by various cytokines (TNF-α and IL-1β) and KC 
in cremaster muscle (22). LSP1 also has a function in dome formulation of endothelium, a pro-
cess that is important in neutrophil migration into the inflamed organs (7, 101, 115). Because the 
role of LSP1 in acute lung inflammation especially the neutrophil migration has not been exam-
ined, I hypothesized that LSP1 deficiency will inhibit acute lung inflammation in mice through 
inhibition of neutrophil migration.
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4. OBJECTIVES 
The role of LSP1 in acute lung inflammation has not been studied. Therefore, in this 
study, I proposed to investigate LSP1 expression in normal and acute inflammation lung of hu-
man and mice. Another purpose is to examine the role of LSP1 in LPS-induced acute lung in-
flammation in mouse model. 
5. RESEARCH QUESTIONS 
 Is the expression of LSP1 altered in inflamed lungs compared the normal lungs? 
 Does LSP1 have a function in neutrophil migration, microvascular permeability and pa-
thology of LPS-induced acute lung inflammation in mouse model? 
  
27 
 
6. MATERIALS AND METHODS 
6.1. Materials 
Twelve to sixteen-week-old male wild-type and LSP1 deficiency (LSP1
/
) mice strain 
129/SVJ were obtained from Dr. Jenny Jongstra-Bilen at University of Toronto and transferred 
to the Department of Pharmacology, College of Medicine, University of Saskatchewan. Autop-
sied normal and septic human lung (n= 5 each group) were obtained from the Department of Pa-
thology in the College of Medicine, University of Saskatchewan. Vetalar (ketamine hydrochlo-
ride injection U.S.P, Bioniche company, Canada), Rompun (xylazine, Bayer company, Canada), 
lipopolysacharide from E. coli 055:B5 (Sigma Aldrich, Saint. Louis, MO, USA), LSP1 antibody 
rabbit anti mouse, reactive in mouse and human (Novus biological, Oakville, ON, Canada), puri-
fied rat anti mouse Ly-6G Ly-6C antibody (Gr-1) (BD Biosciences Pharminogen
TM
 , Mississau-
ga, ON, Canada), secondary antibody Polyclonal goat anti-rabbit immunoglobulins/HRP (horse-
radish peroxidase), secondary antibody polyclonal rabbit anti-ratimmunoglobulins/HRP, primary 
antibody polyclonal rabbit anti human von Willebrant factor (vWF) (Dako, Burlington, ON, 
Canada), Vector® VIP peroxidase substrate kit for peroxidase (Vector laboratories, Burlingame, 
CA, USA),  myeloperoxidase standard from human leukocytes (Sigma Aldrich, Saint. Louis, 
MO, USA), Bio-Plex Pro assays kit (Bio-Rad, Meyerside Drive Mississauga, ON, Canada) were 
purchased commercially. 
6.2. Mouse model of acute lung injury 
Twelve to sixteen-week-old male wild-type 129/SVJ and LSP1
/
 mice were used. 
LSP1
/
 mice were generated as described by Dr. Jongstra-Bilen and colleagues previously (91, 
99). The experiments were approved by the University of Saskatchewan’s Animal Research Eth-
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ics Board and adhered to the Canadian Council on Animal Care guidelines. All mice were 
housed in 12-hour dark/light cycle and fed standard laboratory diet in Animal Care Unit, West-
ern College of Veterinary Medicine, University of Saskatchewan and were allowed to acclima-
tize for one week before treatment.
 
Lipopolysaccharide-induced acute lung inflammation mouse model were designed as 
described previously (116, 117). Briefly, 80 µg of LPS in 80µl saline was instilled intranasally 
for each mouse to induce acute lung inflammation in wild-type (WT; n=10) and LSP1
/
 
(LSP1
/
; n=11) mice. Saline 0.9% (80µl/mouse) was used as a sham for negative control groups 
(7 WT and 10 LSP1
/
mice). After nine hours of the treatment, all of mice were injected 
100mg/kg ketamine and 10mg/kg xylazine intraperitoneally (ip.) to euthanize. Following this, 
cardiac puncture blood, lungs and bronchoalveolar lavage (BAL) fluid were collected. We have 
also collected mouse lungs from LPS intranasally treated mice after 12 and 24 hour to examine 
the expression of LSP1 (n=5 each).
 
Table 6.1. The mouse experimental design 
Phenotype of mice Number (N= 38) Intranasal treatment 
Wild-type 129/SvJ n = 7 80 µl sterile sodium chloride 0.9% 
Wild-type 129/SvJ n = 10 80 µl LPS from E. coli 055:B5(1 µg/µl) 
LSP1
/ n = 10 80 µl sterile sodium chloride 0.9% 
LSP1
/ n = 11 80 µl LPS from E. coli 055:B5 (1 µg/µl) 
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Figure 6.1. Schematic summary of acute lung injury mouse model 
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Figure 6.2. Schematic summary of sample collection and target in mouse experiment 
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6.3. Investigate LSP1 expression in normal and acute inflamed lungs of human and mice 
6.3.1. LSP1 immunohistochemistry 
LSP1 expression in mouse and human lung sections was examined by immunohisto-
chemistry using an LSP1 antibody (Novus biological, Oakville, ON, Canada). The immunohisto-
chemistry protocol was adjusted from a previous paper (118). Briefly, the sections were de-
paraffinized followed by quenching of endogenous peroxidase activity and were treated with 
pepsin. Following 1 hour blocking non-specific binding with 1% bovine serum albumin (BSA), 
the sections were treated primary antibody (20 µg/ml LSP1 antibody) and appropriate secondary 
antibody (1.5 µg/ml polyclonal goat anti-rabbit immunoglobulins/HRP). The color development 
was carried out with Vector® VIP peroxidase substrate kit. While some sections were stained 
with methyl green, the others were examined without nuclear staining to assess whether LSP1 is 
present in the nucleus. The controls included staining with the anti-endothelial marker, vWF, 
serving as a positive control, or IgG isotype antibody matching control instead of LSP1 primary 
antibody or omission of both primary and secondary antibodies serving as negative controls. Al-
so, lungs from LSP1
/
 mice stained with LSP1 antibody acted as an important negative control 
for the non-specific staining by the antibody. 
6.3.2. Western blot analyses for pLSP1 and LSP1 
Frozen mouse lungs were homogenized in T-PER tissue protein extraction reagent, pro-
tease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, USA.) as described pre-
viously (119). The Western blot procedure was modified from a previous protocol (72). Briefly, 
lysate was mixed with equal volume of 2X Laemmli sample buffer (4% SDS, 20% glycerol, 10% 
2-mercaptoethanol, 0.004% bromphenol blue and 0.125 M Tris HCl, pH approximate 6.8) (Sig-
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ma Aldrich, Saint. Louis, MO, USA) before being loaded on 12% SDS-PAGE gel. After that, 
separated proteins in the gel were transferred onto Hypond
TM
-ECL nitrocellulose membrane (GE 
healthcare, Germany). Next, 5% bovine serum albumin in Tris-buffered saline (TBS) Tween 
0.1% was used to block non-specific binding. 
To detect total LSP1 (n = 6 each group), the membranes were then incubated with pol-
yclonal LSP1 antibody rabbit anti mouse (1:500, Novus biological, Oakville, ON, Canada) and 
secondary antibody polyclonal goat anti-rabbit immunoglobulins/HRP (1:2000, Dako, Burling-
ton, ON, Canada). Incubation without primary antibody was used as a negative control. Also, 
lung lysates from LSP1
/
 mice incubated with LSP1 antibody acted as an important negative 
control for the non-specific binding by the LSP1 antibody. The detection blots were performed 
with Amersham ECL western blotting detection reagents Kit (GE Healthcare, Germany). Finally, 
the membranes were exposed under autoradiography Hyperfilm ECL (GE Healthcare, Germany).
 
For pLSP1 detection, the probed membrane was stripped with blot restore membrane 
rejuvenation kit (Millipore, MA, USA.) prior to be pre-probed with phosphorylated LSP1 p-ser 
252 antibody (1:500, Novus biological, Oakville, ON, Canada) and secondary antibody polyclo-
nal goat anti-rabbit immunoglobulins/HRP as above. 
Finally, all membranes were stripped again and incubated with affinity purified rabbit 
anti β-actin antibody loading control (1:5000, abcam, Cambridge, MA., USA.) and secondary 
antibody polyclonal goat anti-rabbit immunoglobulins/HRP. β-actin, an abundant house-keeping 
gene’s product expressed in all cells, was used to examine the equal total amount of protein 
loaded of each sample. Densitometry quantification was performed using ImageJ software to 
evaluate relative density of pLSP1, LSP1 expression level. 
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6.3.3. Human neutrophil isolation 
Human neutrophils were isolated following the previously published protocols (120). 
Briefly, intravenous human blood was donated from healthy volunteers. Neutrophils were isolat-
ed based on density gradient principle. Histopaque H1119, H1083 and H1077 (Sigma Aldrich, 
Saint. Louis, MO, USA), adjusted to a density of 1.119 g/ml, 1.083 g/ml and 1.077 g/ml, respec-
tively were carefully overlaid from the bottom to the top in order and blood was placed in the 
uppermost. After being centrifuged at 700g for 10 minutes in 4
o
C, neutrophils were aspirated in 
the layer between H1083 and H1119. The collection was centrifuged at 700g for 10 minutes in 
4
o
C to collect neutrophils in pellet. Erythrocyte contaminants were lysed by distilled water isoto-
nicity and neutrophils were restored by NaCl in phosphate buffer, pH=7.2. Then neutrophils 
were washed twice in 1X phosphate buffer saline (PBS), pH = 7.2 before being resuspended in 1 
ml RPMI 1640 medium (Lonza company, USA). 
Trypan blue was used to assess live cell quantity. Total number of viable cell collected 
= average number of viable cell/1mm
2
 in haemocytometer x 10
4
 x dilution factor with trypan 
blue x 1ml. Next, the solution was diluted to reach final concentration at 10
6
 cells/ml. After that 
100µl of cells were cytospun into slide and were stained with a Hemacolor stain set (EMD 
Chemicals, Gibbstown, NJ) for differential leukocyte count in 10 fields at 400 magnification. 
The isolated neutrophils were used when purity was 95% or more.  
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Figure 6.3. Human neutrophil experimental design 
6.3.4. Immune gold electron microscopy 
Human neutrophils and mouse lungs were assessed for the expression of LSP1. The 
isolated neutrophils treated with LPS, and mouse lungs were fixed in 2% paraformaldehyde with 
0.1% glutaraldehyde in 0.1M sodium cacodylate buffer for 3 hours at 4

C. After being dehydrat-
ed, the neutrophils were infiltrated with white resin. Next, samples were sectioned at a thickenss 
of 100nm and placed on nickel grids. Non-specific bindings were blocked by BSA 1% in Tris 
buffered saline before one hour incubation in LSP1 antibody (40µg/ml). Negative control with-
out LSP1 antibody also was examined. After 3 washes in Tris buffer saline, the sections were 
incubated for 1 hour in 20nm gold-conjugated anti rabbit secondary antibody with 1:100 dilution 
factors. Following that, samples were incubated in 2% aqueous uranyl acetate, an indicator for 
negative staining then Reynold’s lead citrate to enhance the electron-scattering properties of bio-
logical components inside the cells. The micrographs were imaged using EM410 electron micro-
scope (Philips company, Holland) operated at 60 KV connecting a 622 F/O TV display (Gatan, 
Pleasanton, CA 94566, USA.). 
Human neutrophil 
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LPS (1µg/ml) 
Immune-gold electron 
microscopy 
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6.4. Examine the role of LSP1 in LPS-induced acute lung inflammation in mouse model 
6.4.1. Histopathological analysis 
Right bronchus of mouse lung was ligated with a thread before left lung was instilled 1 
ml of cold 4% paraformaldehyde in situ through trachea. After left lung was inflated, right lung 
was cut and stored at -80

C for analysis later on. Left lung was fixed in 4% paraformaldehyde, 
processed and embedded in paraffin. All sections (5µm thickness) were prepared and placed on 
coated glass slides. Sections were stained with hematoxylin and eosin for histopathological ex-
amination. Histopathology scoring was adjusted from previous description (117). 
Table 6.2. Key for histopathology scoring 
Grade Lung inflammatory degree 
0 Normal architecture. 
1 Diffuse reaction in alveolar walls, congestion 
1-10 neutrophils/field in peribronchial vascular space (magnification 1000). 
2 11-20 neutrophils/field, congestion, slight thickening alveolar wall 
3 21-30 neutrophils/field,  congestion, thickening alveolar wall, light epithelial damage 
4 ≥31 neutrophils/field, congestion, thickening alveolar wall with more than 10% of 
lung consolidated, epithelial damage. 
 
6.4.2. Blood and BAL cell counts 
Briefly, after trachea was exposed, lungs were lavaged three times with 0.5 ml of cold 
Hank’s balanced salt solution (HBSS) with NaHCO3(Sigma, UK) and the BAL was centrifuged 
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at 1,500g for 10 minutes at 4
o
C. Supernatants were collected and stored at -80
o
C for protein, 
chemokine and cytokine assay later on. Total leukocytes in BAL fluid were counted by using 
hemocytometer. Cells were resuspended at 10
6
/ml with HBSS. 100µl of these solutions were cy-
tospun onto microscope slides and stained with Wright-Giemsa Hemacolor stain set (EMD 
Chemicals, Gibbstown, NJ) for differential leukocyte count (neutrophils, basophils, eosinophils, 
monocytes and lymphocytes) in 4 random fields at 400 magnification each mouse. 
Mouse peripheral blood collected through cardiac puncture was kept in heparinized 
tubes. The total number of leukocytes/ml of blood was counted with a haemocytometer after 
erythrocyte hemolysis with 2% acetic acid. Simultaneously, blood smear was stained with 
Wright-Giemsa method (EMD Chemicals, Gibbstown, NJ) for differential leukocyte count in 10 
fields at 400 magnification. 
6.4.3. Lung myeloperoxidase (MPO) quantification 
MPO assay was followed as previous protocol (121). Shortly, the lung homogenates in 
50mM HEPES (Invitrogen Life technologies, Burlington, ON, Canada) were centrifuged at 900g 
for 20 minutes at 4
o
C and the pellet was resuspended and rehomogenised in 0.5% cetyltrimethyl 
ammonium chloride (CTAC) solution. MPO colorimetric assay was performed using 3, 3’, 5, 5’-
tetramethylbenzidine (TMB) as substrate for H2O2 under low pH conditions. Reaction was 
stopped by 1M H2SO4 and read at 450nm OD by NOVOstar software, Bio-Rad machine. Results 
were expressed as units of MPO per mg of lung tissue. 
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6.4.4. Gr-1 immunohistochemistry staining 
The mouse lung sections were also stained with Gr-1 anti-neutrophil antibody to deter-
mine neutrophil migration into perivascular and peribronchial compartments. The immunohisto-
chemistry protocol was adjusted from a previous paper (118). Briefly sections were de-
paraffinized followed by quenching of endogenous peroxidase activity and were treated with 
pepsin. Following 1 hour blocking non-specific binding with 1% bovine serum albumin (BSA), 
the sections were treated with primary antibody (0.40 µg/ml Gr-1 antibody) and appropriate sec-
ondary antibody (13 µg/ml polyclonal rabbit anti-rat immunoglobulins/HRP). The color devel-
opment was carried out with Vector® VIP peroxidase substrate kit. The controls included stain-
ing with the anti-endothelial marker, vWF, serving as a positive control, or rat IgG2b, κ antibody 
isotype matching control instead of Gr-1 primary antibody or omission of both primary and sec-
ondary antibodies serving as negative controls. The degree of neutrophil infiltration was ex-
pressed as a Gr-1
+
 staining score in 4 randomly chosen fields per mouse in magnification 1000 
(n=5), modified method from a previous paper (122). 
Table 6.3. Gr-1
+ 
neutrophil scoring system 
Score Number of neutrophils/field (Magnification 1000) 
0 0 
1 1-10 
2 11-20  
3 21-30 
4 ≥ 31 
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6.4.5. Cytokine and chemokine analyses in BAL fluid and lung homogenates 
We quantified KC, MCP-1, MIP-1α, MIP-1β and TNF-α in right lungs and BAL fluid 
collected from the mice with Bio-Plex Pro Assay Kit (BioRad, Meyerside Drive, Mississauga, 
ON, Canada). Briefly, the lungs were ground in lysing solution, sonicated and centrifuged for the 
collection of supernatant. The cytokine and chemokines were quantified in 50µl following manu-
facturer’s instructions.  
6.4.6. Pulmonary microvascular permeability assay 
Protein analysis in BAL fluid was carried out to evaluate vascular permeability (Bio-
Rad, Protein Assay Dye Reagent Concentration, USA). The principle of protein determination 
was according to method of Bradford (123). Briefly, 10µl of each standard or samples was pipet-
ted into separate wells of 96-wells microtiter plates. After addition of 200 µl of dye reagent and 5 
minute-incubation, the absorbance was measured at 595nm by NOVOstar software, Bio-Rad 
machine. 
6.4.7. Western blot analyses for pp38MAPK and p38MAPK 
Frozen mouse lungs were homogenized in T-PER Tissue Protein Extraction Reagent, 
protease and phosphatase inhibitor cocktail (Thermo Scientific, Rockford, USA) as described in 
a paper (119). The Western blot procedure was modified from a previous protocol (72) as de-
scribed above. 
To detect total and phosphorylated p38 mitogen-activated protein kinase (pp38MAPK) 
(n=4 each group), membranes were incubated with purified monoclonal rabbit anti phospho-
p38MAPK (Thr180/Tyr182) antibody (1:1,000, Cell signaling technology, Danvers, MA 01923, 
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USA.) at 4

C with gentle shaking overnight and secondary antibody polyclonal goat anti-rabbit 
immunoglobulins/HRP for 1 hour (1:2000, Dako, Burlington, ON, Canada). Following that, the 
probed membranes were stripped with blot restore membrane rejuvenation kit prior to be pre-
probed with purified rabbit anti p38MAPK antibody (1:10,000, Enzo Life Sciences, Farming-
dale, NY 11735, USA.) and secondary antibody polyclonal goat anti-rabbit immunoglobu-
lins/HRP as above. 
Finally, all membranes were stripped again and incubated with immunogen affinity pu-
rified rabbit anti β-actin antibody loading control (1:5000, abcam, Cambridge, MA., USA.) and 
secondary antibody polyclonal goat anti-rabbit immunoglobulins/HRP. β-actin, an abundant 
house-keeping gene’s product expressed in all cells, was used to examine the equal total amount 
of protein loaded of each sample. Incubation without primary antibody was used as a negative 
control. Densitometry quantification was performed using ImageJ software to evaluate relative 
density of pp38MAPK, p38MAPK expression level. 
6.4.8. Statistical analysis: 
Statistical analysis was performed using GraphPad Prism software version 5.04 (San 
Diego, CA, USA). Quantitative results were expressed as mean and error bars represented stand-
ard error. Normal distribution of residuals was tested by histogram and Shapiro-Wilk test. Data 
were analyzed by Analysis Of Variance (ANOVA) followed by Bonferroni multiple comparison 
test. Student t test or Wilcoxon Signed Rank Test was used to compare two groups. The critical 
value of α was set to 0.05 as a significant difference (two-tailed). 
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7. RESULTS 
7.1. LSP1 expression in normal and acute inflamed lungs of human and mice 
7.1.1. LSP1 expression is increased in septic human lungs 
Because to our knowledge there is no information on LSP1 expression in normal hu-
man lungs, we used immunohistochemistry to bridge this gap. Autopsied normal human lungs 
showed LSP1 on alveolar septum, alveolar macrophages, and blood cells (Figure 7.1C, E). Septic 
lungs showed massive migration of neutrophils and obliteration of normal lung architecture. 
Neutrophils in the alveoli and blood vessels showed robust expression of LSP1 (Figure 7.1D, F). 
The semi-quantification of immunohistochemical LSP1 staining showed significant increase in 
staining of LSP1 in all of the septic human lungs compared to the normal human lung controls 
(Figure 7.2). Interestingly, LSP1 was extensively localized into the nuclei of neutrophils. The 
LSP1 expression was more intense on nucleus than on cytoplasm. 
Histopathology on hematoxyline and eosin-staining was also done to confirm presence 
of inflammatory signs of septic human lungs. Healthy human lungs showed normal histologic 
structure with thin alveolar septa along with intact septal cells and clear alveolar spaces (Figure 
7.3A). Septic human lungs showed exuberant migration of inflammatory cells, especially neutro-
phils in alveolar and peribronchial vascular spaces and obliteration of lung architecture (Figure 
7.3B). 
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Figure 7.1. Human lung immunohistochemistry for LSP1 
Lung section from humans was stained with IgG isotype antibody matched control and second-
ary antibody (A) shows only green blue color of methyl green counter staining serving as a nega-
tive control. Figure (B) depicts positive staining on only endothelium of lung section stained with 
vWF serving as a positive control. LSP1 staining (arrows) is noticed in alveolar septum and al-
veolar macrophage (C) and blood cells (E) in lungs from a non-septic human. Figure D and F 
show increased number of neutrophils expressing LSP1 (arrows) recruited into a septic lung. 
The LSP1 staining is mostly nuclear (F). Original magnification 400, 1000X. N=5 in each 
group  
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Figure 7.2. Statistical analysis semi-quantitative LSP1 expression scoring of human lung sec-
tions. 
In general, LSP1 expression increases in macrophage, neutrophils, endothelium and airway epi-
thelium of septic human lungs comparing to normal human lung control. We classified that: 0: 
no staining, 1+: light staining, 2+: moderate staining, 3+: strong staining, 4+: very strong 
staining. Asterisk (*) indicates significant difference from normal lung group (P<0.05). n=5 
each group. 
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Figure 7.3. Histopathological examination of human lungs stained with hematoxylin and eosin 
Healthy human lung (A) showed normal histologic structure with thin alveolar septa along with 
intact septal cells and clear alveolar spaces. Septic human lung (B) showed massive migration of 
inflammatory cells, especially neutrophils in alveolar and peribronchial vascular spaces and 
obliteration of lung architecture. Original magnification 100 (A) and 400 (B). (As: Alveolar 
space, Bv: Blood vessel) 
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7.1.2. LSP1 and phosphorylated LSP1 expression is increased in LPS-induced lung in-
flammation in mouse 
After examining the LSP1 expression in human lungs, we explored LSP1 expression in 
a mouse model of LPS-induced lung inflammation, and compared it to the expression in lungs 
from normal mice. In contrast to saline-treated mice lungs, the inflamed lungs showed increased 
staining of LSP1 on alveolar septa, airway epithelium, and vascular endothelium at 9 hour post-
LPS treatment (Figure 7.5). In particular, the staining was highly intense in neutrophils, macro-
phages and airway epithelium (Figure 7.5). The expression of LSP1 remained intense in various 
lung cells 12 and 24 hours post-LPS treatment (Figure 7.6). The LSP1 was localized mostly in 
nuclei of airway epithelial cells, macrophages and neutrophils at 24 hours post-LPS treatment. 
The semi-quantification of immunohistochemical LSP-1 staining showed significant increase in 
staining of LSP1 in all of the LPS-treated mouse lungs compared to the saline-treated controls 
(Figure 7.7). Immuno-electron microscopy confirmed the presence of LSP1 in endothelial cells 
and neutrophils in the lungs of LPS-treated mouse (Figure 7.8) 
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Figure 7.4. Controls for LSP1 immunohistochemistry staining of mouse lungs 
Mouse lung section stained with vWF antibody (A) shows only positive reaction in blood vessel 
(arrow), serving as a control for the protocol. Figure (B) shows wild-type mouse lung section 
stained of with IgG isotype matched control instead of LSP1 antibody. Lungs from saline treated 
LSP1
/
 mouse (C) and LPS treated LSP1
/
 mouse (D) were stained with LSP1 antibody show 
no positive staining. Figure B, C and D serve as negative controls, which rules out non-specific 
binding of primary and secondary antibodies. Abbreviation: Br, bronchiolar epithelium; Bv. 
Blood vessel. Original magnification 400. 
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Figure 7.5. Mouse lung immunohistochemistry 
Saline-treated WT mouse lung shows basal expression of LSP1 (arrows) in alveolar septum (A), 
macrophage (A, inset), bronchiolar epithelium (Br; C, E) and vascular endothelium (Bv, C). The 
LSP1 staining is much increased in at 9 hours post-LPS treatment in WT mouse lung in alveolar 
septum (B), macrophage (B, inset) and neutrophil (D, inset), vascular endothelium (D) and 
bronchiolar epithelium (Br; D, F). The high magnification views (E, F) show increased cyto-
plasmic and nuclear localization of LSP1 in bronchiolar epithelial cells. Abbreviation: Br, bron-
chiolar epithelium; Bv. Blood vessel. Original magnification 400, 1000. n=5 in each group  
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Figure 7.6. IHC for LSP1 in wild-type mouse lungs from 12-24 hour post- LPS treatment 
LSP1 is expressed (arrows) in septum and bronchiolar epithelium (Br) and vascular (Bv) endo-
thelium at 12 hours (A) and 24 hours (B) post-LPS treatment. Higher magnification views show 
nuclear staining of LSP1 in bronchiolar epithelium (C), macrophages and neutrophils (D) at 24 
hour post-LPS treatment. Abbreviation: Br, bronchiolar epithelium; Bv. Blood vessel. Original 
magnification 400, 1000. n=5 in each group 
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Figure 7.7. Statistical analysis semi-quantitative LSP1 expression scoring of wild-type mouse 
lung sections 
In general, LSP1 expression increases in macrophage, neutrophils, endothelium and airway epi-
thelium after LPS challenging 9, 12, 24 hours comparing to saline control. We did not observe 
any neutrophils in alveolar space and peribronchial vascular space in saline normal group. We 
classified that: 0: no staining, 1+: light staining, 2+: moderate staining, 3+: strong staining, 
4+: very strong staining. Asterisk (*) indicates significant difference from wild-type saline 
(P<0.05). n=5 each group.  
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Figure 7.8. Immuno-gold electron microscopy for LSP1in a mouse lung 
The section from a mouse lung treated with LPS shows staining for LSP1 (arrows) in an endo-
thelial cell (E) and neutrophil (N). AS: Alveolar space. Original magnification 13,000. 
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Because of lack of frozen tissues from all the time points, we were able to compare on-
ly the LSP1 expression via western blots in normal and the 9 hour post-LPS mice. While western 
blots confirmed lack of LSP1 protein in the LSP1
/ 
mice (Figure 7.9), the expression of phos-
phorylated as well as total LSP1 was significantly increased upon LPS treatment (Figure 7.9).   
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 Total LSP1 
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Figure 7.9. The LSP1 observation in mouse lungs (A) after saline or LPS 9 hour treatment was 
confirmed by western blot following by densitometry quantification 
Mouse lungpLSP1 and total LSP1 express one major band at about 52 kD. β-actin was used as a 
housekeeping gene which is not altered by any treatments. This protein serves as a loading con-
trol, identical amounts of whole cell lysates. β-actin observed band size is about 47 kD. Adjusted 
density of the relative abundance of pLSP1 over total LSP1 was shown in (C). Relative density of 
pLSP1 (B) and total LSP1 (D) were corrected for β-actin levels within each sample. Data were 
expressed as mean ± standard error (n=6 each group). Asterisk (*) indicates significant differ-
ence from wild-type saline (P<0.05). 
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7.1.3. LSP-1 expression in human peripheral blood neutrophils 
We further probed isolated human neutrophils for LSP1 expression with immuno-gold 
electron microscopy. Compared to the control neutrophils that showed LSP1 in their nucleus and 
cytoplasm (Figure 7.10), the LPS-treated neutrophils showed more staining for LSP1 in their nu-
cleus and cytoplasm (Figure 7.11). In addition, there was increased LSP1 staining on the plasma 
membrane of LPS-treated neutrophils (Figure 7.12), which is similar to previous report in trans-
formed B lymphoma cell line and normal thymocytes (96). 
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Figure 7.10. Immuno-gold electron microscopy for LSP1 for control neutrophil 
Saline-treated neutrophil shows LSP1 staining (arrows) in nucleus (Nu) and cytoplasm. The 
boxed area magnified above shows LSP1 staining. Original magnification 13,000. 
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Figure 7.11. Immunogold electron microscopy for LSP1 for LPS-treated neutrophil 
LPS-treated neutrophil shows increased LSP1 staining (arrows) compared to the saline-treated 
neutrophil (Figure 7.10) in nucleus (Nu) and cytoplasm. The boxed area magnified above shows 
LSP1 staining. Original magnification 13,000. 
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Figure 7.12. Immunogold electron microscopy for LSP1 for LPS-treated neutrophil 
LPS-treated neutrophil shows increased LSP1 staining (arrows) on plasma membrane and the 
nucleus (Nu). Original magnification 13,000 
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7.2. Examine the role of LSP1 in LPS-induced acute lung inflammation in mouse model 
7.2.1. LSP1 deficiency reduces histologic signs of lung inflammation 
First, we conducted histopathology assessment on lungs harvested from the mice in this 
study. As shown in hematoxylin and eosin staining pictures (Figure 7.13, Figure 7.14), while the 
lungs from saline-treated WT or LSP1
/
 mice showed normal architecture, the LPS-treatment 
induced congestion, damage to epithelium and infiltration of neutrophils in the septa and peri-
vascular spaces. The lungs from LSP1
/ 
mice treated with LPS showed considerable less in-
flammation and histopathology compared to LPS-treated WT mice. The extent of differences 
was also indicated by the fact that even though the lungs were lavaged, the lungs from WT-LPS 
mice compared to LSP1
/
-LPS mice had many neutrophils in the alveoli. 
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Figure 7.13. Histopathological examination of mouse lungs stained with hematoxylin and eosin 
Lungs from wild-type (A) and LSP1
/ 
mice (B) treated with saline shows no inflammation and 
normal architecture. Wild-type mouse lung 9 hour post LPS (C) shows more severe inflammatory 
than LSP1
/
 mouse lung challenged LPS (D) as indicated by thickening of alveolar septum due 
to more neutrophil accumulation. (As: Alveolar space, Bv: Blood vessel, Br: Bronchiole, PVS: 
Peribronchial vascular space). Original magnification 100 
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Figure 7.14. Statistical analysis semi-quantitative histopathology scoring of inflammation reac-
tion in mouse lungs after saline or 9-hour LPS treatment 
Asterisk (*) indicates significant difference (P<0.001). Lesions were scored for both severity of 
inflammatory cell infiltrate and distribution: 0 (normal), 1 (minimal), 2 (mild), 3 (moderate), 4 
(severe) as described above. 
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7.2.2. LSP1 deficiency reduces neutrophils recruitment into inflamed lungs 
We examined the role of LSP1 in LPS-induced migration of neutrophils into lung alve-
oli. As shown in Figure 7.15, while there were no differences in total and different leukocytes 
count in peripheral blood between saline-treated WT and LSP1
/
 mice, peripheral blood neutro-
phil percentage were higher in WT and LSP1
/
 mice at 9 hour post-LPS treatment compared to 
their respective controls (P<0.001).  
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Figure 7.15. Peripheral leukocyte count data 
LSP1
/ 
does not affect peripheral blood cell quantity in LPS-treated mice. However, we ob-
served that the number of neutrophils in peripheral blood of wild-type mice was little higher than 
that of LSP1
/
 mice after 9 hour LPS treatment. Neutrophilia was observed in both phenotypes 
of mice. Asterisk (*) indicates significant difference (P<0.001). 
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As depicted in Figure 7.16, LPS treatment increased the numbers of total cells in BAL 
fluid of WT and LSP1
/
 mice compared to their respective controls (WT groups P < 0.001, 
LSP1
/
 groups P<0.05). Furthermore, the total cell counts were higher in BAL fluid from WT-
LPS mice compared to LSP1
/
-LPS mice (P<0.001). Similarly, the absolute neutrophil numbers 
but not monocyte numbers were significantly higher in BAL fluid of WT-LPS mice compared to 
LSP1
/
-LPS mice (P < 0.001). 
  
62 
 
 
Figure 7.16. Total and differential leukocyte count in bronchoalveolar lavage fluid 
Compared with saline treatment, a substantial increase in total leukocyte (A), mainly neutrophil 
(B) in the airway after 9 hours post-LPS intranasal instillation was observed in both phenotypes 
of mice. LSP1 deficiency reduces recruitment of neutrophils in LPS-treated lungs in comparison 
with wild-type. There was an increase but not significant change in the number of macrophages 
in bronchoalveolar lavage fluid (C). Asterisk (*) indicates significant difference.  
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It is known that many neutrophils are trapped in the vasculature or interstitium of in-
flamed lungs in addition those that have migrated into the alveoli and are flushed with BAL. 
Therefore, we used MPO estimation as a surrogate for the lung tissue neutrophils. As described 
in Figure 7.17, compared to respective saline controls, higher MPO activity was detected in 
lungs of WT-LPS (P<0.001) but not LSP1
/
-LPS mice. Lungs from WT-LPS mice also had 
higher MPO activity compared to LSP1
/
-LPS mice (P<0.05). We obtained morphological evi-
dence of presence of neutrophils in lung tissues with Gr-1 immunohistochemistry (Figure 7.18). 
The data showed more neutrophils in lung sections from WT-LPS mice than from LSP1
/
-LPS 
mice (Figure 7.19).  
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Figure 7.17. Myeloperoxidase content in broncho-alveolar larvage fluid 
LSP1 induced myeloperoxidase activity in LPS administrated lungs. Asterisk (*) indicates signif-
icant difference.  
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Figure 7.18. Representative pictures of Gr-1 immunohistochemistry staining of mouse lungs 
Lungs from wild-type (A) and LSP1
/
mice (B) treated with saline show only occasional neutro-
phils. Wild-type mouse lung 9 hour post LPS administration (C, E) shows more neutrophils were 
trapped in the airway than LSP1
/
 mouse lung (D, F) after 9 hour LPS instillation. LSP1
/
 re-
duces neutrophil accumulation. (As: Alveolar space, Bv: Blood vessel, Br:  Bronchiole, PVS: 
Peribronchial vascular space). Original magnification 400, 1000. n=5 each group. 
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Figure 7.19. Semiquantitative representation of Gr-1 lung immunohistochemical staining 
Acceleration of neutrophil infiltration in the lungs at 9-hour after LPS treatment was evidenced 
by grading Gr-1-positive cells per 1000X field. Data shows preventive effects of LSP1 deficiency 
towards neutrophils infiltration in lungs undergone 9 hour LPS treatment. 
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7.2.3. LSP1 deficiency reduces expression of TNF-α but not KC, MCP-1, MIP-1α, MIP-
1β in BAL 
To determine the mechanisms underlying the effects of LSP1 on neutrophil migration 
into inflamed lungs, we quantified KC, MCP-1, MIP-1α, MIP-1β, and TNF-α in BAL fluid and 
lung homogenates. As demonstrated in Figure 7.20, while there were no differences in KC con-
centrations in BAL fluid of LPS-treated mice compared to their respective controls, TNF-α, 
MIP-1α, MIP-1β were significantly increased following LPS-treatment of both WT and LSP1/ 
mice compared to their respective controls (P<0.05). MCP-1 in BAL fluid was increased in WT 
but not LSP1
/
 mice following LPS treatment. Except TNF-α (P<0.05), there were no differ-
ences in the concentrations of any of the other inflammatory mediators between the WT and 
LSP1
/
 mice treated with LPS. 
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Figure 7.20. Proinflammatory cytokine and chemokine productions in BAL fluid 
LSP1 enhance TNF-α in BAL fluid. Asterisk (*) indicates significant difference. Abbreviation: 
TNF-α: Tumor necrosis factor-α, KC: Keratinocyte-derived chemokine, MCP-1: Monocyte 
chemoattractant protein 1, MIP-1: macrophage inflammatory protein 1.  
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7.2.4. LSP1 deficiency did not affect expression of TNF-α, KC, MCP-1, MIP-1α, MIP-1β 
in lung homogenates 
In lung tissues, the LPS treatment of WT and LSP1
/
 mice significantly increased con-
centrations of KC, MCP-1, MIP-1α, MIP-1β, and TNF-α compared to their respective saline con-
trols (P<0.05). There, however, were no differences in the concentrations of these inflammatory 
mediators between WT and LSP1
/
 mice in the normal or LPS-treatment (Figure 7.21). 
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Figure 7.21. Proinflammatory cytokines and chemokines in mouse lung homogenates 
Lungs of both mouse phenotypes treated with LPS show significant higher TNF-α, KC, MCP-1, 
MIP-1α, and MIP-1β in comparison with saline negative control, respectively. LSP1 did not af-
fect chemokine in remaining lung tissue. Asterisk (*) indicates significant difference.  
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7.2.5. LSP1 deficiency does not regulate vascular permeability in inflamed lungs 
In the LPS administered animals, protein concentration in BAL fluid increased signifi-
cantly compared to saline control in both types of mice (P<0.01) (Figure 7.22). However, there 
was no significant difference in protein level between wild-type and LSP1
/ 
mice after treatment 
with LPS. 
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Figure 7.22. Protein concentration in bronchoalveolar lavage fluid 
Both types of mice challenged with LPS showed significantly higher protein content than saline 
control. LSP1 did not affect substaintially total protein leakage in BAL fluid at this time point. 
Asterisk (*) indicates significant difference. 
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7.2.6. LSP1 deficiency affects phosphorylation of p38MAPK in inflamed lungs 
MAPKAP2 as well as p38MAPK was known as an upstream substrate for LSP1 (11, 
90). Inhibition of p38MAPK can reduce endothelial LSP1 phosphorylation (91). Therefore, in 
our study, densitometric quantification of Western blots for phosphorylated Thr180/Tyr182 
p38MAPK and total p38MAPK of mouse lung in saline and LPS 9 hour administration was per-
formed (Figure 7.23). Densitometry quantification data (Figure 7.23) shows that in wild-type 
groups but not LSP1
/
 groups, phosphorylated p38MAPK level increased at 9 hour LPS treat-
ment compared with saline control (P<0.05). There was no significant difference between wild-
type and LSP1
/
 mice regarding the adjust density of phosphorylated p38MAPK and 
p38MAPK. 
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 Total p38MAPK 
 β actin loading control 
 
 
 
 
 
 
Figure 7.23. Western blots (A) for phosphorylated p38MAPK and total p38MAPK of mouse 
lungs after saline or LPS 9 hour administration following by densitometry quantification. 
pp38MAPK and p38MAPK molecular weight are about 43 kD and 38 kD, respectively. β-actin 
was used as a housekeeping gene which is not altered by any treatments. This protein serves as a 
loading control, identical amounts of whole cell lysates. β-actin observed band size is about 47 
kD. Relative density of phosphorylated p38MAPK was corrected for β-actin levels within each 
sample (B). Densitometry quantification of phosphorylated pp38MAPK over total p38MAPK in 
mouse lungs was depicted in (C). p38MAPK phosphorylation increased due to LPS treatment in 
both phenotypes of mice. Data were expressed as mean ± standard error (n=4 each group). As-
terisk (*) indicates significant difference from wild-type saline (P<0.05).  
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8. DISCUSSION 
We provide evidence for a role for LSP1 in LPS-induced neutrophil migration but not 
vascular permeability in acute lung inflammation. The data show that LSP1 may be influencing 
lung inflammation through phosphorylation of p38MAPK and TNF-α expression but without 
altering expression of KC, MCP-1, MIP-1α, and MIP-1β. The expression of LSP1 was increased 
in lungs from LPS-treated mice and also in lungs from septic humans. The expression was espe-
cially intense in neutrophils and their nuclei. These data add to our understanding of mechanisms 
of neutrophil recruitment in inflamed lungs as well as biology of LSP1. 
We used a described model of LPS-induced acute lung inflammation (116, 117). Stud-
ies on distribution of LSP1 protein on inflamed lung have been limited (1, 88, 100).We used 
immunohistology to show LSP1 in airway epithelium, alveolar macrophages and septal cells. 
The expression of LSP1 was increased in epithelium, endothelium and inflammatory cells in-
cluding neutrophils. The increased expression of LSP1 in airway epithelium and inflammatory 
cells such as neutrophils was sustained up to 24 hours post-LPS treatment. The expression of 
LSP1 was also increased in autopsied lungs from septic humans. The immunohistologic increase 
was confirmed with Western blots on mouse lung tissue homogenates. The expression of total 
LSP1 protein was significantly increased at 9 hours post-LPS treatment. Within the total LSP1, 
phosphorylated LSP1 was also significantly increased in lung homogenates from LPS-treated 
mice to suggest activation of LSP1. Taken together, our data showed that lung inflammation al-
ters expression of LSP1 and increases the amount of phosphorylated LSP1. 
Immunohistologic data showed intense expression of LSP1 in neutrophil nuclei in au-
topsied septic lungs. Interestingly, there is very limited information available on the subcellular 
localization of LSP1 (101, 124). Therefore, recognizing the limiting resolution of light micro-
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scope, we used immuno-gold electron microscopy to show that LSP1 is present on the plasma 
membrane and nucleus of lung vascular endothelium and neutrophils. Some authors proposed 
that LSP1 interacted with cytoskeleton through F-actin binding, which have functions in cell mo-
tility and inter-cellular interactions (124). It is also believed that endothelial LSP1 can translocate 
from nucleus and cytosol to the cytoskeleton to form endothelial domes to allow neutrophils 
transendothelial migration (101). Although our studies do not inform on the role of nuclear 
LSP1, the data showing increased staining of LSP1 in neutrophils in inflamed lungs creates a 
need to further clarify the mechanisms and the reasons for the movement of LSP1 into the nucle-
us. 
Endotoxin-induced lung injury is characterized by migration of neutrophils into lung 
tissues, and migration of activated neutrophils, though necessary for host defense, is credited 
with excessive tissue damage. Therefore, significant scientific effort is underway to more pre-
cisely understand the molecules regulating neutrophil migration into inflamed lungs. There are 
data to show the role of selectins and integrins (67, 69), along with various chemokines, in multi-
step paradigm of recruitment of neutrophils into the lungs (45, 74, 125-127). Our data show that 
LSP1
/
 reduces lung pathology and also influences migration of neutrophils into inflamed lungs. 
LSP1 deficiency reduced migration of neutrophils into BAL and also into lung vascular and in-
terstitial compartments based on analyses of BAL and lung tissues. Lung tissue neutrophil con-
tent was also assessed through myeloperoxidase quantification and staining of lung tissues with 
Gr-1 antibody as previous papers (128-131). Taken together, these data suggest that LSP1 influ-
ences tissue and alveolar recruitment of neutrophils into inflamed lungs. The reduced alveolar 
and tissue migration of neutrophils suggests an interference of LSP1 at the level of interaction of 
endothelium and neutrophils as both of these cells express LSP1. Such a contention is supported 
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by whole-mount staining of cremaster muscle tissue or 2-photon microscopy showed a double-
fold increase in the quantity of domes in wild-type mice than that in LSP1
/
 mice after TNF-α or 
IL-1β administration (101). Moreover, transmission electron microscopy technique illustrated 
that endothelial domes completely enveloped neutrophils in wild-type but not in LSP1
/
 mice 
(101). We demonstrate localization of LSP1 on the plasma membranes of neutrophils and endo-
thelial cells, and speculate whether LSP1 is involved in direct physical engagement of endotheli-
um with the neutrophils. 
We aimed to explore the mechanisms through which LSP1 may be regulating migra-
tion of neutrophils. First, we examined phosphorylation of p38MAPK in lung homogenates be-
cause LPS instillation causes increased phosphorylated p38MAPK and inhibition of p38MAPK 
phosphorylation reduces lung inflammation and cytokine expression (132-136). Our data show 
reduced phosphorylated p38MAPK in LPS-treated LSP1
/
 mice compared the treatment 
matched WT mice. Interestingly, inhibition of phosphorylated p38MAPK leads to diminished 
phosphorylation of LSP1 (91). Therefore, endothelial LSP1 phosphorylation is clearly a down-
stream molecule of p38MAPK signaling, and the relationship between the two may underlie re-
duced migration of neutrophils in LSP1
/
 mice (23, 91, 101). These data need to be strengthened 
through studies of p38MAPK on normal and activated neutrophils isolated from wild-type and 
LSP1
/ 
mice and the interaction of such neutrophils with isolated lung microvascular endotheli-
um in future. 
In this study, we demonstrated the LSP1 function in LPS-induced acute lung injury in 
mouse model by comparing normal mice and mice lack of LSP1. In saline control sham groups, 
mice lack of LSP1 developed normally and had the same results as wild-type mice. Therefore, 
the differences between wild-type and LSP1 deficient mice are the consequence of LSP1 absence 
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but not because of problem from deficient procedure of gene targeting. The immunoblot results 
indicated that wild-type and LSP1
/
 mice did not have a significant difference in phosphorylated 
p38MAPK. LSP1 phosphorylation augmented considerably after 9 hour LPS treatment. It is 
identified that the association of LSP1 with the cytoskeleton, especially F-actin in mouse bases 
on its basic COOH-terminal site (10) which is the phosphorylation area. The binding sites of 
over-express LSP1 with F-actin are in three main regions: amino acid 181-245, amino acid 246-
295, and amino acid 306-339 (97). The site within the residues 231–330 binds LSP1 tightly with 
F-actin (6). In our study, we focus on LSP1 phosphorylation ser 252 in human, corresponding to 
ser 243 in mouse, which was proven a major phosphorylation site of LSP1 (11). Therefore, taken 
together, it can be concluded that LSP1 is one of the conditional requirements for neutrophil 
transmigration, an important stage involved acute lung inflammation mechanism. 
To further understand the mechanisms of reduced neutrophil migration in LPS-treated 
LSP1
/
 mice, we examined expression of KC, MCP-1, MIP-1α, MIP-1β, and TNF-α, which 
have many important functions on acute lung injury (125-127). We found increased concentra-
tions of KC, MCP-1, MIP-1α, MIP-1β, and TNF-α in lung homogenates of LPS-treated mice but 
there was no impact of LSP1 deficiency on their expression. The recruitment of neutrophils into 
alveoli is directed through chemokines and we examined KC, MCP-1, MIP-1α, MIP-1β, and 
TNF-α concentration in BAL fluid. Except TNF-α, there was no effect of LSP1 deficiency on 
secretion of these inflammatory mediators. In other words, this finding can suggest that TNF-α, a 
cytokine production of activated monocyte, macrophage (137), have more complex and im-
portant relationship with LSP1 in upregulating neutrophils infiltration than other cytokines and 
chemokines in this acute lung inflammation model.  In other organs, neutrophil recruitment 
through post-capillary venules of LSP1
/
 mice is restricted even when activated by various cy-
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tokines (TNF-α and IL-1β) and chemokine (KC, MIP2) suggesting that endothelial LSP1 has a 
significant role in transendothelial migration of neutrophils (22, 23). It is interesting to note that 
while LPS-treated increased MCP-1 concentrations in the BAL of WT mice, there was no differ-
ence between the control and LPS-treated LSP1
/
 mice. The lack of upregulation of MCP-1 may 
have implications for the recruitment of monocytes/macrophages that occurs in the later parts of 
lung inflammation induced by a single challenge with LPS, and needs to be studied further. 
Intriguingly, we found that LSP1 deficiency does not protect the lung against increased 
vascular permeability. While our study does not provide explanation for this observation, there 
are previous data to show that lung vascular permeability may be independent of neutrophil mi-
gration (81, 138). It has also been reported that every neutrophil immigrating in KC, TNF-α or 
MIP-2-treated cremaster muscles of LSP1
/
 mice caused significantly higher vascular permea-
bility (22, 101, 115). Furthermore, while permeability reduction was known to be a result of leu-
kocyte infiltration decrease in mesentery (139), it was reported that besides leukocyte emigra-
tion, there were other factors affect the increase of plasma leakage such as histamine (140, 141). 
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Figure 8.1. A schematic depicting LSP1 expression and its effects in acute lung inflammation 
In addition to activate macrophage and epithelium in the airway, LPS can penetrate pulmonary 
capillary through an injured blood-air barrier (142) then binds to TLRs such as TLR4 molecule 
on neutrophils and endothelium (143, 144). It was proven before that LPS activates TLR4 which 
increases phosphorylation of p38MAPK (145, 146). Event downstream of p38MAPK activation 
is LSP1 phosphorylation which results in enhancing neutrophil migration. The host lung tissue is 
demolished due to an excessive extravasation of neutrophils and their products. MPO and TNF-
α represent adverse effect mechanism on neutrophil recruitment and activation. 
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9. SUMMARY 
In summary, the main purpose of this study was to determine the role of LSP1 in acute 
lung inflammation through its function in neutrophil migration and pathology in murine LPS-
induced lung inflammation. We investigated that LSP1 expression is modulated in acute lung 
injury and LSP1 deficiency reduces neutrophil migration into LPS-induced acute lung inflamma-
tion in mouse model. Therefore, the proposed hypotheses are proven true. We expect that the re-
sults presumably apply to find a solution for lung inflammation. Inhibiting LSP1 could be one of 
the new therapeutic targets for acute lung inflammation involving LPS, an endotoxin in the Gram 
negative bacteria wall. 
10. LIMITATION OF THE STUDY 
These series of experiments only focus on studying LSP1 expression and its functions 
in an acute phase of lung inflammation which prominent neutrophil extravasation is one of the 
important hallmarks. Therefore, further studies are required to strengthen the results in future and 
to explore the impact of LSP1 on monocyte/macrophage recruitment in the later phase of acute 
lung inflammation. 
11. FUTURE STUDIES 
In my study, LPS-induced acute lung inflammation experiment has indicated clearly the 
function of LSP1 in neutrophil recruitment and its effects on severity of acute lung inflammation. 
In the future, it is necessary to study LSP1 role in later phases of lung inflammation revolving 
around some longer time-point LPS administrations to elucidate mechanistic endpoint. It would 
be interesting to first look at LSP1 function in other inflammatory cell populations such as mac-
rophages, and lymphocytes in addition to neutrophils in inflamed lungs to elucidate the whole 
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effects of LSP1 in the all aspects of lung inflammation. The expression of LSP1 on macrophage 
also leads to a question whether this protein has a function on macrophage migration and 
phagocytosis of apoptotic neutrophils. Moreover, the similar vascular permeability level of wild-
type and LSP1
/
 mice suggests that such studies will need to be conducted over longer time pe-
riods. A comprehensive study on the roles of LSP1 on other aspects of lung inflammation in dif-
ferent models such as asthma also needs to be studied. 
Additionally, the immunohistochemistry results showing an increase expression of 
LSP1 in mouse lungs by 9 hours of LPS treatment raise a question if there are alterations in ex-
pression of LSP1 in other lung inflammation contexts such as an asthma situation. Moreover, the 
similar expression of LSP1 across human and mouse lungs further suggests that LSP1 probably 
functions similarly in acute lung inflammation in human and mouse in this model. Based upon 
LSP1 expression studied by immunohistochemistry and immune-gold electron microscopy 
method in this study, the next experiment should be identification the expression of LSP1 in 
normal and inflamed lungs of other animal species such as horse, cattle, pigs and chicken infect-
ed withseveral different pathogens. It is necessary to investigate the functions of LSP1 in 
pulmonary physiology and pathology in domestic animals, which could lead to new therapeutic 
approaches for lung diseases. 
Lastly there is need to delineate the precise mechanism of LSP1 signaling pathway that 
effect neutrophil functions and apoptosis in respond to other pathogens under in vitro conditions. 
Studies of p38MAPK on normal and activated neutrophils isolated from wild-type and LSP1
/
 
mice and the interaction of such neutrophils with isolated lung microvascular endothelium 
should be designed to strengthen the results. Moreover, combating microbes is one of important 
functions of neutrophils to protect the host in the pathogen in the early phase of infection (147). 
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In a previous study on proteomic analysis on human neutrophil granules, LSP1 was observed 
particularly in gelatinase granules and specific granules associating actin cytoskeleton activity 
and phagosomes (102). Therefore, examination of LSP1 and NETs association due to exocytosis 
of the granules in response to bacteria can be a potential experiment in future to indicate LSP1 
functions. Moreover, neutrophils can clear the pathogen by their productions and ion movement, 
which also attract other immune cells to protect the body in next stage of immune system (56). 
However, overproduction can damage the host tissue (148). Recent works have shown a contro-
versy of LSP1 functions on superoxide anion production of neutrophil under different treatments 
such as PMA and KC (10). Therefore, other set of questions is whether LSP1 plays a role in pro-
ductions such as ROS by activated neutrophils in response to some pathogens. Finally, because 
LSP1 has been shown to have some conflicting association with apoptosis in B and T cells (112, 
114), mechanistic data on the role of LSP1 in regulation of neutrophil apoptosis which prolongs 
lifespan of activated neutrophils is credited with increase in tissue pathology are required to be 
studied. 
  
84 
 
12. PRESENTATIONS AND AWARDS 
- Poster presentation: L.N.P. Khanh, C. Shankaramurthy, L. Liu and B. Singh. “Leukocyte-
Specific Protein 1 (LSP1) regulates neutrophil migration in acute lung inflammation”.  
 Presented at “WCVM Graduate Student Research Poster Days”, March 13-14th, 
2013, Western College of Veterinary Medicine, University of Saskatchewan. 
Achieved 2
nd
 place poster in Cell/Tissue pathobiology theme. 
 Presented at “20th Annual Life & Health Sciences research day”, 15th March 2013, 
College of Medicine, University of Saskatchewan. 
 Presented at the Experimental Biology 2013 Annual Conference, in Boston, Massa-
chusetts, MA 02210, USA, 20-24
th
 April 2013. 
 
- Poster presentation: L.N.P. Khanh, C. Shankaramurthy, L. Liu and B. Singh. “Role of Leuko-
cyte Specific Protein 1 in acute lung inflammation”. 
 Presented at “5th Prairie Infectious Immunology Networking Conference”, 19th- 
21st September 2012. Hosted by “Infectious Immunology Research Interest Group 
& Immunology and Infectious Disease Research Group”, celebrated in Moose Jaw, 
Saskatchewan. 
 Presented at “Students’ poster competition”, 3rd October 2012. College of graduate 
studies and research, University of Saskatchewan. 
 
- Poster presentation: L.N.P. Khanh, C. Shankaramurthy, L. Liu and B. Singh. “Role of Leuko-
cyte Specific Protein 1 in neutrophil recruitment in lipopolysaccharide-induced lung in-
flammation”. 
 Presented at “WCVM Graduate Student Research Poster Days”, March 13-14, 2012, 
Western College of Veterinary Medicine, University of Saskatchewan.  
 Presented at “19th Annual Life & Health Sciences research day”, 9th March 2012, 
College of Medicine, University of Saskatchewan. Achieved 3rd place poster in 
Immunology theme. 
 
- Seminar “Role of Leukocyte-Specific Protein 1 in acute lung inflammation” in Department of 
Veterinary Biomedical Sciences, Western College of Veterinary Medicine, University of Sas-
katchewan on 14
th
 November 2012. 
 
 
 
  
85 
 
13. REFERENCES 
1. Pulford K., J. M., Banham A. Haralambieva H. , E. & Mason D. Y. 1999. Lymphocyte-
specific protein 1: a specific marker of human leucocytes. J. Immunology 96: 262-271. 
2. Wong, M. J., I. A. Malapitan, B. A. Sikorski, and J. Jongstra. 2003. A cell-free binding 
assay maps the LSP1 cytoskeletal binding site to the COOH-terminal 30 amino acids. 
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1642: 17-24. 
3. May, W., J. Korenberg, X. Chen, L. Lunsford, W. Wood, A. Thompson, R. Wall, and C. 
Denny. 1993. Human lymphocyte-specific pp52 gene is a member of a highly conserved 
dispersed family. Genomics 15(3): 515-520. 
4. Jongstra-Bilen, J., A. J. Young, R. Chong, and J. Jongstra. 1990. Human and mouse 
LSP1 genes code for highly conserved phosphoproteins. J Immunol 144: 1104-1110. 
5. Brennan, L., and J. Jongstra. 1996. Low expression of the Lspl gene in early mouse T-
lymphomas induced by iV-methyl-./V-nitrosourea. Cardnogenesls 17: 771-777. 
6. Jongstra-Bilen, J., and J. Jongstra. 2006. Leukocyte-specific protein 1 (LSP1): a regulator 
of leukocyte emigration in inflammation. Immunol Res 35: 65-74. 
7. Liu, L., D. C. Cara, J. Kaur, E. Raharjo, S. C. Mullaly, J. Jongstra-Bilen, J. Jongstra, and 
P. Kubes. 2005. LSP1 is an endothelial gatekeeper of leukocyte transendothelial 
migration. The Journal of experimental medicine 201: 409-418. 
8. Chen, M. B., C. Li, W. X. Shen, Y. J. Guo, W. Shen, and P. H. Lu. 2011. Association of a 
LSP1 gene rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 
cases and 35,671 controls. Mol Biol Rep 38: 4687-4695. 
86 
 
9. Smith, A. L., L. Ganesh, K. Leung, J. Jongstra-Bilen, J. Jongstra, and G. J. Nabel. 2007. 
Leukocyte-specific protein 1 interacts with DC-SIGN and mediates transport of HIV to 
the proteasome in dendritic cells. Journal of Experimental Medicine 204: 421-430. 
10. Hannigan, M., L. J. Zhan, Y. X. Ai, and C. K. Huang. 2001. Leukocyte-specific gene 1 
protein (LSP1) is involved in chemokine KC-activated cytoskeletal reorganization in 
murine neutrophils in vitro. Journal of leukocyte biology 69: 497-504. 
11. Wu, Y., L. Zhan, Y. Ai, M. Hannigan, M. Gaestel, C. K. Huang, and J. A. Madri. 2007. 
MAPKAPK2-mediated LSP1 phosphorylation and FMLP-induced neutrophil 
polarization. Biochem Biophys Res Commun 358: 170-175. 
12. Centers for Disease Control and Prevention, 2003. Cigarette smoking-attributable 
morbidity---United States, 2000. MMWR. Morbidity and mortality weekly report 52: 842-
844. 
13. Matthay, M. A., and R. L. Zemans. 2011. The acute respiratory distress syndrome: 
pathogenesis and treatment. Annu Rev Pathol 6: 147-163. 
14. Moreland, J. G., G. Bailey, W. M. Nauseef, and J. P. Weiss. 2004. Organism-specific 
neutrophil-endothelial cell interactions in response to Escherichia coli, Streptococcus 
pneumoniae, and Staphylococcus aureus. J Immunol 172: 426-432. 
15. Fligger, J. M., A. S. Waldvogel, H. Pfister, and T. W. Jungi. 1999. Expression of 
inducible nitric oxide synthase in spontaneous bovine bronchopneumonia. Veterinary 
pathology 36: 397-405. 
16. Catterall, J. R. 1999. Streptococcus pneumoniae. Thorax 54: 929-937. 
17. Russo, T. A., B. A. Davidson, R. L. Priore, U. B. Carlino, J. D. Helinski, and P. R. 
Knight, 3rd. 2000. Capsular polysaccharide and O-specific antigen divergently modulate 
87 
 
pulmonary neutrophil influx in an Escherichia coli model of gram-negative pneumonitis 
in rats. Infection and immunity 68: 2854-2862. 
18. Donihi, A. C., D. Raval, M. Saul, M. T. Korytkowski, and M. A. DeVita. 2006. 
Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized 
patients. Endocrine practice : official journal of the American College of Endocrinology 
and the American Association of Clinical Endocrinologists 12: 358-362. 
19. Rochat, T. S., and J. P. Janssens. 2012. [Systemic and oropharyngeal side effects of 
inhaled corticosteroids]. Revue medicale suisse 8: 2219-2223. 
20. Grommes, J., and O. Soehnlein. 2011. Contribution of neutrophils to acute lung injury. 
Mol Med 17: 293-307. 
21. Cai, S., R. L. Zemans, S. K. Young, G. S. Worthen, and S. Jeyaseelan. 2009. Myeloid 
differentiation protein-2-dependent and -independent neutrophil accumulation during 
Escherichia coli pneumonia. American journal of respiratory cell and molecular biology 
40: 701-709. 
22. Lei, X., M. Hossain, S. M. Qadri, and L. Liu. 2012. Different microvascular permeability 
responses elicited by the CXC chemokines MIP-2 and KC during leukocyte recruitment: 
role of LSP1. Biochem Biophys Res Commun 423: 484-489. 
23. Wang, J., H. Jiao, T. L. Stewart, M. V. Lyons, H. A. Shankowsky, P. G. Scott, and E. E. 
Tredget. 2007. Accelerated wound healing in leukocyte-specific, protein 1-deficient 
mouse is associated with increased infiltration of leukocytes and fibrocytes. Journal of 
leukocyte biology 82: 1554-1563. 
24. Ashbaugh, D. G., D. B. Bigelow, T. L. Petty, and B. E. Levine. 1967. Acute respiratory 
distress in adults. Lancet 2: 319-323. 
88 
 
25. Flori, H. R., D. V. Glidden, G. W. Rutherford, and M. A. Matthay. 2005. Pediatric acute 
lung injury: prospective evaluation of risk factors associated with mortality. American 
journal of respiratory and critical care medicine 171: 995-1001. 
26. Randolph, A. G. 2009. Management of acute lung injury and acute respiratory distress 
syndrome in children. Critical care medicine 37: 2448-2454. 
27. Kumar, V., A. K. Abbas, N. Fausto, and J. C. Aster. 2010. Pathologic basis of disease-
The lung. Saunders Elsevier. 
28. Bersten, A. D., C. Edibam, T. Hunt, and J. Moran. 2002. Incidence and mortality of acute 
lung injury and the acute respiratory distress syndrome in three Australian States. 
American journal of respiratory and critical care medicine 165: 443-448. 
29. Brun-Buisson, C., C. Minelli, G. Bertolini, L. Brazzi, J. Pimentel, K. Lewandowski, J. 
Bion, J. A. Romand, J. Villar, A. Thorsteinsson, P. Damas, A. Armaganidis, and F. 
Lemaire. 2004. Epidemiology and outcome of acute lung injury in European intensive 
care units. Results from the ALIVE study. Intensive care medicine 30: 51-61. 
30. Ribble, C. S., A. H. Meek, E. D. Janzen, P. T. Guichon, and G. K. Jim. 1995. Effect of 
time of year, weather, and the pattern of auction market sales on fatal fibrinous 
pneumonia (shipping fever) in calves in a large feedlot in Alberta (1985-1988). Canadian 
journal of veterinary research = Revue canadienne de recherche veterinaire 59: 167-172. 
31. Rubenfeld, G. D., and M. S. Herridge. 2007. Epidemiology and outcomes of acute lung 
injury. Chest 131: 554-562. 
32. Ware, L. B., and M. A. Matthay. 2000. The acute respiratory distress syndrome. The New 
England journal of medicine 342: 1334-1349. 
89 
 
33. Matthay, M. A., L. B. Ware, and G. A. Zimmerman. 2012. The acute respiratory distress 
syndrome. The Journal of clinical investigation 122: 2731-2740. 
34. Diep, B. A., L. Chan, P. Tattevin, O. Kajikawa, T. R. Martin, L. Basuino, T. T. Mai, H. 
Marbach, K. R. Braughton, A. R. Whitney, D. J. Gardner, X. Fan, C. W. Tseng, G. Y. 
Liu, C. Badiou, J. Etienne, G. Lina, M. A. Matthay, F. R. DeLeo, and H. F. Chambers. 
2010. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine 
leukocidin-induced lung inflammation and injury. Proceedings of the National Academy 
of Sciences of the United States of America 107: 5587-5592. 
35. Wiener-Kronish, J. P., and J. F. Pittet. 2011. Therapies against virulence products of 
Staphylococcus aureus and Pseudomonas aeruginosa. Seminars in respiratory and 
critical care medicine 32: 228-235. 
36. Zachary, J. F., and M. D. McGavin. 2012. Pathologic basis of Veterinary disease-
Mechanism of microbial infections, Elsevier mosby. 
37. Moss, M., B. Bucher, F. A. Moore, E. E. Moore, and P. E. Parsons. 1996. The role of 
chronic alcohol abuse in the development of acute respiratory distress syndrome in 
adults. JAMA : the journal of the American Medical Association 275: 50-54. 
38. Calfee, C. S., M. A. Matthay, M. D. Eisner, N. Benowitz, M. Call, J. F. Pittet, and M. J. 
Cohen. 2011. Active and passive cigarette smoking and acute lung injury after severe 
blunt trauma. American journal of respiratory and critical care medicine 183: 1660-
1665. 
39. Christie, J. D., M. M. Wurfel, R. Feng, G. E. O'Keefe, J. Bradfield, L. B. Ware, D. C. 
Christiani, C. S. Calfee, M. J. Cohen, M. Matthay, N. J. Meyer, C. Kim, M. Li, J. Akey, 
K. C. Barnes, J. Sevransky, P. N. Lanken, A. K. May, R. Aplenc, J. P. Maloney, and H. 
90 
 
Hakonarson. 2012. Genome wide association identifies PPFIA1 as a candidate gene for 
acute lung injury risk following major trauma. PloS one 7: e28268. 
40. Glavan, B. J., T. D. Holden, C. H. Goss, R. A. Black, M. J. Neff, A. B. Nathens, T. R. 
Martin, and M. M. Wurfel. 2011. Genetic variation in the FAS gene and associations with 
acute lung injury. American journal of respiratory and critical care medicine 183: 356-
363. 
41. Tanaka, H., M. Nishino, and T. E. Dahms. 2002. Physiologic responses to small emboli 
and hemodynamic effects of changes in deformability of polymorphonuclear leukocytes 
in isolated rabbit lung. Microvasc Res 63: 81-90. 
42. Li, W., J. Li, M. Ashok, R. Wu, D. Chen, L. Yang, H. Yang, K. J. Tracey, P. Wang, A. E. 
Sama, and H. Wang. 2007. A cardiovascular drug rescues mice from lethal sepsis by 
selectively attenuating a late-acting proinflammatory mediator, high mobility group box 
1. J Immunol 178: 3856-3864. 
43. Bhatia, M., and S. Moochhala. 2004. Role of inflammatory mediators in the 
pathophysiology of acute respiratory distress syndrome. J Pathol 202: 145-156. 
44. Zhang, B., Z. Y. Liu, Y. Y. Li, Y. Luo, M. L. Liu, H. Y. Dong, Y. X. Wang, Y. Liu, P. T. 
Zhao, F. G. Jin, and Z. C. Li. 2011. Antiinflammatory effects of matrine in LPS-induced 
acute lung injury in mice. Eur J Pharm Sci. 
45. Puneet, P., S. Moochhala, and M. Bhatia. 2005. Chemokines in acute respiratory distress 
syndrome. American Journal of Physiology-Lung Cellular and Molecular Physiology 
288: L3-L15. 
46. Ware, L. B. 2006. Pathophysiology of acute lung injury and the acute respiratory distress 
syndrome. Seminars in respiratory and critical care medicine 27: 337-349. 
91 
 
47. DiStasi, M. R., and K. Ley. 2009. Opening the flood-gates: how neutrophil-endothelial 
interactions regulate permeability. Trends in immunology 30: 547-556. 
48. Rittirsch, D., M. A. Flierl, and P. A. Ward. 2008. Harmful molecular mechanisms in 
sepsis. Nature reviews. Immunology 8: 776-787. 
49. Imai, Y., K. Kuba, G. G. Neely, R. Yaghubian-Malhami, T. Perkmann, G. van Loo, M. 
Ermolaeva, R. Veldhuizen, Y. H. Leung, H. Wang, H. Liu, Y. Sun, M. Pasparakis, M. 
Kopf, C. Mech, S. Bavari, J. S. Peiris, A. S. Slutsky, S. Akira, M. Hultqvist, R. 
Holmdahl, J. Nicholls, C. Jiang, C. J. Binder, and J. M. Penninger. 2008. Identification of 
oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. 
Cell 133: 235-249. 
50. Dudek, S. M., and J. G. Garcia. 2001. Cytoskeletal regulation of pulmonary vascular 
permeability. J Appl Physiol 91: 1487-1500. 
51. Caudrillier, A., K. Kessenbrock, B. M. Gilliss, J. X. Nguyen, M. B. Marques, M. 
Monestier, P. Toy, Z. Werb, and M. R. Looney. 2012. Platelets induce neutrophil 
extracellular traps in transfusion-related acute lung injury. The Journal of clinical 
investigation 122: 2661-2671. 
52. Mantovani, A., M. A. Cassatella, C. Costantini, and S. Jaillon. 2011. Neutrophils in the 
activation and regulation of innate and adaptive immunity. Nature reviews. Immunology 
11: 519-531. 
53. Matthay, M. A., and G. A. Zimmerman. 2005. Acute lung injury and the acute respiratory 
distress syndrome - Four decades of inquiry into pathogenesis and rational management. 
American journal of respiratory cell and molecular biology 33: 319-327. 
92 
 
54. van den Berg, J. M., and T. W. Kuijpers. 2011. Educational paper: Defects in number and 
function of neutrophilic granulocytes causing primary immunodeficiency. Eur J Pediatr 
170: 1369-1376. 
55. Tizard, I. R. 2004. Veterinary Immunology - an introduction. s. edition, ed. Saunders. 24-
34. 
56. Segal, A. W. 2005. How neutrophils kill microbes. Annual review of immunology 23: 
197-223. 
57. El-Benna, J., P. M. Dang, and M. A. Gougerot-Pocidalo. 2008. Priming of the neutrophil 
NADPH oxidase activation: role of p47phox phosphorylation and NOX2 mobilization to 
the plasma membrane. Seminars in immunopathology 30: 279-289. 
58. Tizard, I. R. 2013. Veterinary immunology-Innate immunity. Elsevier. 
59. Kasama, T., Y. Miwa, T. Isozaki, T. Odai, M. Adachi, and S. L. Kunkel. 2005. 
Neutrophil-derived cytokines: potential therapeutic targets in inflammation. Current drug 
targets. Inflammation and allergy 4: 273-279. 
60. Wright, H. L., R. J. Moots, R. C. Bucknall, and S. W. Edwards. 2010. Neutrophil 
function in inflammation and inflammatory diseases. Rheumatology (Oxford) 49: 1618-
1631. 
61. Shaw, D. E., M. A. Berry, B. Hargadon, S. McKenna, M. J. Shelley, R. H. Green, C. E. 
Brightling, A. J. Wardlaw, and I. D. Pavord. 2007. Association between neutrophilic 
airway inflammation and airflow limitation in adults with asthma. Chest 132: 1871-1875. 
62. Ordonez, C. L., T. E. Shaughnessy, M. A. Matthay, and J. V. Fahy. 2000. Increased 
neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: Clinical 
93 
 
and biologic significance. American journal of respiratory and critical care medicine 
161: 1185-1190. 
63. Brinkmann, V., U. Reichard, C. Goosmann, B. Fauler, Y. Uhlemann, D. S. Weiss, Y. 
Weinrauch, and A. Zychlinsky. 2004. Neutrophil extracellular traps kill bacteria. Science 
303: 1532-1535. 
64. Abbas, A. K., A. H. Lichtman, and S. Pillai. 2012. Cellular and Molecular Immunology. 
Elsevier Saunders. 
65. Carlow, D. A., K. Gossens, S. Naus, K. M. Veerman, W. Seo, and H. J. Ziltener. 2009. 
PSGL-1 function in immunity and steady state homeostasis. Immunological reviews 230: 
75-96. 
66. Laszik, Z., P. J. Jansen, R. D. Cummings, T. F. Tedder, R. P. McEver, and K. L. Moore. 
1996. P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, 
lymphoid, and dendritic lineage and in some nonhematopoietic cells. Blood 88: 3010-
3021. 
67. Hirose, M., T. Murai, and H. Kawashima. 2007. Elevation of rat plasma P-selectin in 
acute lung injury. Biochim Biophys Acta 1772: 382-389. 
68. Zarbock, A., K. Singbartl, and K. Ley. 2006. Complete reversal of acid-induced acute 
lung injury by blocking of platelet-neutrophil aggregation. The Journal of clinical 
investigation 116: 3211-3219. 
69. Xu, N., A. Rahman, R. D. Minshall, C. Tiruppathi, and A. B. Malik. 2000. beta(2)-
Integrin blockade driven by E-selectin promoter prevents neutrophil sequestration and 
lung injury in mice. Circulation research 87: 254-260. 
94 
 
70. Nieminen, J., C. St-Pierre, P. Bhaumik, F. Poirier, and S. Sato. 2008. Role of galectin-3 
in leukocyte recruitment in a murine model of lung infection by Streptococcus 
pneumoniae. J Immunol 180: 2466-2473. 
71. Ramamoorthy, C., S. S. Sasaki, D. L. Su, S. R. Sharar, J. M. Harlan, and R. K. Winn. 
1997. CD18 adhesion blockade decreases bacterial clearance and neutrophil recruitment 
after intrapulmonary E. coli, but not after S. aureus. Journal of leukocyte biology 61: 167-
172. 
72. Janardhan, K. S., G. D. Appleyard, and B. Singh. 2004. Expression of integrin subunits 
alphav and beta3 in acute lung inflammation. Histochemistry and cell biology 121: 383-
390. 
73. Olson, T. S., and K. Ley. 2002. Chemokines and chemokine receptors in leukocyte 
trafficking. Am J Physiol Regul Integr Comp Physiol 283: R7-28. 
74. Rose, C. E., Jr., S. S. Sung, and S. M. Fu. 2003. Significant involvement of CCL2 (MCP-
1) in inflammatory disorders of the lung. Microcirculation 10: 273-288. 
75. Doerschuk, C. M. 2000. Leukocyte trafficking in alveoli and airway passages. Respir Res 
1: 136-140. 
76. Motosugi, H., L. Graham, T. W. Noblitt, N. A. Doyle, W. M. Quinlan, Y. Li, and C. M. 
Doerschuk. 1996. Changes in neutrophil actin and shape during sequestration induced by 
complement fragments in rabbits. American Journal of Pathology 149: 963-973. 
77. Ali, W. H., Q. Chen, K. E. Delgiorno, W. Su, J. C. Hall, T. Hongu, H. Tian, Y. Kanaho, 
G. Di Paolo, H. C. Crawford, and M. A. Frohman. 2013. Deficiencies of the lipid-
signaling enzymes phospholipase D1 and D2 alter cytoskeletal organization, macrophage 
phagocytosis, and cytokine-stimulated neutrophil recruitment. PloS one 8: e55325. 
95 
 
78. Wang, Q., and C. M. Doerschuk. 2001. The p38 mitogen-activated protein kinase 
mediates cytoskeletal remodeling in pulmonary microvascular endothelial cells upon 
intracellular adhesion molecule-1 ligation. J Immunol 166: 6877-6884. 
79. Wang, Q., M. Yerukhimovich, W. A. Gaarde, I. J. Popoff, and C. M. Doerschuk. 2005. 
MKK3 and -6-dependent activation of p38alpha MAP kinase is required for cytoskeletal 
changes in pulmonary microvascular endothelial cells induced by ICAM-1 ligation. 
American journal of physiology. Lung cellular and molecular physiology 288: L359-369. 
80. Shirai, A., R. Fujita, and T. Hayase. 2005. Simulation model for flow of neutrophils in 
pulmonary capillary network. Technology and health care : official journal of the 
European Society for Engineering and Medicine 13: 301-311. 
81. Mackarel, A. J., K. J. Russell, C. S. Brady, M. X. FitzGerald, and C. M. O'Connor. 2000. 
Interleukin-8 and leukotriene-B(4), but not formylmethionyl leucylphenylalanine, 
stimulate CD18-independent migration of neutrophils across human pulmonary 
endothelial cells in vitro. American journal of respiratory cell and molecular biology 23: 
154-161. 
82. Esposti, M. D. 2002. The roles of Bid. Apoptosis 7: 433-440. 
83. Duffin, R., A. E. Leitch, S. Fox, C. Haslett, and A. G. Rossi. 2010. Targeting granulocyte 
apoptosis: mechanisms, models, and therapies. Immunological reviews 236: 28-40. 
84. Janssen, W. J., L. Barthel, A. Muldrow, R. E. Oberley-Deegan, M. T. Kearns, C. 
Jakubzick, and P. M. Henson. 2011. Fas determines differential fates of resident and 
recruited macrophages during resolution of acute lung injury. American journal of 
respiratory and critical care medicine 184: 547-560. 
96 
 
85. Park, D., C. Z. Han, M. R. Elliott, J. M. Kinchen, P. C. Trampont, S. Das, S. Collins, J. J. 
Lysiak, K. L. Hoehn, and K. S. Ravichandran. 2011. Continued clearance of apoptotic 
cells critically depends on the phagocyte Ucp2 protein. Nature 477: 220-224. 
86. Scannell, M., M. B. Flanagan, A. Destefani, K. J. Wynne, G. Cagney, C. Godson, and P. 
Maderna. 2007. Annexin-1 and peptide derivatives are released by apoptotic cells and 
stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 178: 4595-
4605. 
87. Franz S, G. U., Munoz LE, Sheriff A, Beer A, Kalden JR, Herrmann M. 2006. Apoptosis 
and autoimmunity: when apoptotic cells break their silence. Curr Rheumatol Rep. 
8(4):245-7. 
88. Jongstra, J., G. F. Tidmarsh, J. Jongstra-Bilen, and M. M. Davis. 1988. A new 
lymphocyte-specific gene which encodes a putative Ca2+-binding protein is not 
expressed in transformed T lymphocyte lines. J Immunol 141: 3999-4004. 
89. Jongstra, J., and M. M. Davis. 1988. Molecular genetic analysis of mouse B lymphocyte 
differentiation. UCLA Symp. Mol. Cell. Biol. 56: 261. 
90. Huang, C. K., L. Zhan, Y. Ai, and J. Jongstra. 1997. LSP1 is the major substrate for 
mitogen-activated protein kinase-activated protein kinase 2 in human neutrophils. The 
Journal of biological chemistry 272: 17-19. 
91. Hossain, M., S. M. Qadri, Y. Su, and L. Liu. 2013. ICAM-1-mediated leukocyte adhesion 
is critical for the activation of endothelial LSP1. American journal of physiology. Cell 
physiology 304: C895-904. 
92. Ohira, T., G. Bannenberg, M. Arita, M. Takahashi, T. Van Dyke, G. Stahl, C. Serhan, and 
J. Badwey. 2004. A stable aspirin-triggered lipoxin A4 analog (ATLa) blocks 
97 
 
phosphorylation of leukocyte specific protein 1 (LSP1) in human neutrophils. Faseb 
Journal 18: C160-C160. 
93. McLaughlin, N. J., A. Banerjee, M. R. Kelher, F. Gamboni-Robertson, C. Hamiel, F. R. 
Sheppard, E. E. Moore, and C. C. Silliman. 2006. Platelet-activating factor-induced 
clathrin-mediated endocytosis requires beta-arrestin-1 recruitment and activation of the 
p38 MAPK signalosome at the plasma membrane for actin bundle formation. J Immunol 
176: 7039-7050. 
94. Misener, V. L., A. Wielowieyski, L. A. Brennan, G. Beebakhee, and J. Jongstra. 1998. 
The mouse Lsp1 and Tnnt3 genes are 4.3 kb apart on distal mouse chromosome 7. 
Mammalian genome : official journal of the International Mammalian Genome Society 9: 
846-848. 
95. Malone, C. S., S. A. Omori, D. Gangadharan, and R. Wall. 2001. Leukocyte-specific 
expression of the pp52 (LSP1) promoter is controlled by the cis-acting pp52 silencer and 
anti-silencer elements. Gene 268: 9-16. 
96. Klein, D. P., J. Jongstra-Bilen, K. Ogryzlo, R. Chong, and J. Jongstra. 1989. 
Lymphocyte-specific Ca2+-binding protein LSP1 is associated with the cytoplasmic face 
of the plasma membrane. Molecular and cellular biology 9: 3043-3048. 
97. Zhang, Q., Y. Li, and T. H. Howard. 2000. Human lymphocyte-specific protein 1, the 
protein overexpressed in neutrophil actin dysfunction with 47-kDa and 89-kDa protein 
abnormalities (NAD 47/89), has multiple F-actin binding domains. J Immunol 165: 2052-
2058. 
98 
 
98. Zhang, Q., Y. Li, and T. H. Howard. 2001. Hair-forming activity of human lymphocyte 
specific protein 1 requires cooperation between its caldesmon-like domains and the villin 
headpiece-like domains. Cell motility and the cytoskeleton 49: 179-188. 
99. Jongstra-Bilen, J., V. L. Misener, C. Wang, H. Ginzberg, A. Auerbach, A. L. Joyner, G. 
P. Downey, and J. Jongstra. 2000. LSP1 modulates leukocyte populations in resting and 
inflamed peritoneum. Blood 96: 1827-1835. 
100. Jongstra, J., M. E. Ittel, N. N. Iscove, and G. Brady. 1994. The Lsp1 Gene Is Expressed 
in Cultured Normal and Transformed Mouse Macrophages. Molecular immunology 31: 
1125-1131. 
101. Petri, B., J. Kaur, E. M. Long, H. Li, S. A. Parsons, S. Butz, M. Phillipson, D. Vestweber, 
K. D. Patel, S. M. Robbins, and P. Kubes. 2011. Endothelial LSP1 is involved in 
endothelial dome formation, minimizing vascular permeability changes during neutrophil 
transmigration in vivo. Blood 117: 942-952. 
102. Lominadze, G., D. W. Powell, G. C. Luerman, A. J. Link, R. A. Ward, and K. R. 
McLeish. 2005. Proteomic analysis of human neutrophil granules. Molecular & cellular 
proteomics : MCP 4: 1503-1521. 
103. Wang, C. J., H. Hayashi, R. Harrison, B. Chiu, J. R. Chan, H. L. Ostergaard, R. D. 
Inman, J. Jongstra, M. I. Cybulsky, and J. Jongstra-Bilen. 2002. Modulation of Mac-1 
(CD11b/CD18)-mediated adhesion by the leukocyte-specific protein 1 is key to its role in 
neutrophil polarization and chemotaxis. J Immunol 169: 415-423. 
104. Wang, J., H. Jiao, T. L. Stewart, H. A. Shankowsky, P. G. Scott, and E. E. Tredget. 2008. 
Increased severity of bleomycin-induced skin fibrosis in mice with leukocyte-specific 
protein 1 deficiency. J Invest Dermatol 128: 2767-2776. 
99 
 
105. Howard, T., Y. Li, M. Torres, A. Guerrero, and T. Coates. 1994. The 47-kD protein 
increased in neutrophil actin dysfunction with 47-and 89-kD protein abnormalities is 
lymphocyte-specific protein. Blood 83: 231-241. 
106. Anand, A. R., A. Prasad, R. R. Bradley, Y. S. Deol, T. Nagaraja, X. Ren, E. F. 
Terwilliger, and R. K. Ganju. 2009. HIV-1 gp120-induced migration of dendritic cells is 
regulated by a novel kinase cascade involving Pyk2, p38 MAP kinase, and LSP1. Blood 
114: 3588-3600. 
107. Miyoshi, E. K., P. L. Stewart, P. W. Kincade, M. B. Lee, A. A. Thompson, and R. Wall. 
2001. Aberrant expression and localization of the cytoskeleton-binding pp52 (LSP1) 
protein in hairy cell leukemia. Leukemia Research 25: 57-67. 
108. Hulett, M. D., and P. M. Hogarth. 1998. The second and third extracellular domains of 
FcgammaRI (CD64) confer the unique high affinity binding of IgG2a. Molecular 
immunology 35: 989-996. 
109. McKenzie, S. E., and A. D. Schreiber. 1998. Fc gamma receptors in phagocytes. Curr 
Opin Hematol 5: 16-21. 
110. Danikas, D. D., M. Karakantza, G. L. Theodorou, G. C. Sakellaropoulos, and C. A. 
Gogos. 2008. Prognostic value of phagocytic activity of neutrophils and monocytes in 
sepsis. Correlation to CD64 and CD14 antigen expression. Clinical and experimental 
immunology 154: 87-97. 
111. Qin, H., J. C. Edberg, A. W. Gibson, G. P. Page, L. Teng, and R. P. Kimberly. 2004. 
Differential gene expression modulated by the cytoplasmic domain of Fc gamma RIa 
(CD64) alpha-chain. J Immunol 173: 6211-6219. 
100 
 
112. Jongstra-Bilen, J., A. Wielowieyski, V. Misener, and J. Jongstra. 1999. LSP1 regulates 
anti-IgM induced apoptosis in WEHI-231 cells and normal immature B-cells. Molecular 
immunology 36: 349-359. 
113. Cao, M. Y., F. Shinjo, S. Heinrichs, J. W. Soh, J. Jongstra-Bilen, and J. Jongstra. 2001. 
Inhibition of anti-IgM-induced translocation of protein kinase C beta I inhibits ERK2 
activation and increases apoptosis. The Journal of biological chemistry 276: 24506-
24510. 
114. Sabbagh, L., D. Andreeva, G. D. Laramee, N. A. Oussa, D. Lew, N. Bisson, Y. 
Soumounou, T. Pawson, and T. H. Watts. 2013. Leukocyte-specific protein 1 links TNF 
receptor-associated factor 1 to survival signaling downstream of 4-1BB in T cells. 
Journal of leukocyte biology 93: 713-721. 
115. Lei, X. 2011. The role of LSP1 in microvascular hyperpermeability during neutrophil 
recruitment in vivo. In Department of Pharmacology. University of Saskatchewan. 81. 
116. Suri, S. S., S. Mills, G. K. Aulakh, F. Rakotondradany, H. Fenniri, and B. Singh. 2011. 
RGD-tagged helical rosette nanotubes aggravate acute lipopolysaccharide-induced lung 
inflammation. International journal of nanomedicine 6: 3113-3123. 
117. Szarka, R. J., N. Wang, L. Gordon, P. N. Nation, and R. H. Smith. 1997. A murine model 
of pulmonary damage induced by lipopolysaccharide via intranasal instillation. Journal 
of immunological methods 202: 49-57. 
118. Schneberger, D., D. Lewis, S. Caldwell, and B. Singh. 2011. Expression of toll-like 
receptor 9 in lungs of pigs, dogs and cattle. International journal of experimental 
pathology 92: 1-7. 
101 
 
119. Jepsen, K. J., F. Wu, J. H. Peragallo, J. Paul, L. Roberts, Y. Ezura, A. Oldberg, D. E. 
Birk, and S. Chakravarti. 2002. A syndrome of joint laxity and impaired tendon integrity 
in lumican- and fibromodulin-deficient mice. The Journal of biological chemistry 277: 
35532-35540. 
120. Lokuta, M. A., P. A. Nuzzi, and A. Huttenlocher. 2007. Analysis of neutrophil 
polarization and chemotaxis. Methods Mol Biol 412: 211-229. 
121. Schneider, T., and A. C. Issekutz. 1996. Quantitation of eosinophil and neutrophil 
infiltration into rat lung by specific assays for eosinophil peroxidase and 
myeloperoxidase. Application in a Brown Norway rat model of allergic pulmonary 
inflammation. Journal of immunological methods 198: 1-14. 
122. Mizuno, S., and T. Nakamura. 2005. Prevention of neutrophil extravasation by 
hepatocyte growth factor leads to attenuations of tubular apoptosis and renal dysfunction 
in mouse ischemic kidneys. The American journal of pathology 166: 1895-1905. 
123. Bradford, M. M. 1974. A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 
248-254. 
124. Jongstra-Bilen, J., P. A. Janmey, J. H. Hartwig, S. Galea, and J. Jongstra. 1992. The 
lymphocyte-specific protein LSP1 binds to F-actin and to the cytoskeleton through its 
COOH-terminal basic domain. The Journal of cell biology 118: 1443-1453. 
125. Ward, P. A. 1996. Role of complement, chemokines, and regulatory cytokines in acute 
lung injury. Annals of the New York Academy of Sciences 796: 104-112. 
102 
 
126. Puneet, P., S. Moochhala, and M. Bhatia. 2005. Chemokines in acute respiratory distress 
syndrome. American journal of physiology. Lung cellular and molecular physiology 288: 
L3-15. 
127. Blanchet, X., M. Langer, C. Weber, R. R. Koenen, and P. von Hundelshausen. 2012. 
Touch of chemokines. Frontiers in immunology 3: 175. 
128. Dhaliwal, K., E. Scholefield, D. Ferenbach, M. Gibbons, R. Duffin, D. A. Dorward, A. C. 
Morris, D. Humphries, A. MacKinnon, T. S. Wilkinson, W. A. Wallace, N. van Rooijen, 
M. Mack, A. G. Rossi, D. J. Davidson, N. Hirani, J. Hughes, C. Haslett, and A. J. 
Simpson. 2012. Monocytes control second-phase neutrophil emigration in established 
lipopolysaccharide-induced murine lung injury. American journal of respiratory and 
critical care medicine 186: 514-524. 
129. Lomas-Neira, J., C. S. Chung, M. Perl, S. Gregory, W. Biffl, and A. Ayala. 2006. Role of 
alveolar macrophage and migrating neutrophils in hemorrhage-induced priming for ALI 
subsequent to septic challenge. American journal of physiology. Lung cellular and 
molecular physiology 290: L51-58. 
130. Lomas, J. L., C. S. Chung, P. S. Grutkoski, B. W. LeBlanc, L. Lavigne, J. Reichner, S. H. 
Gregory, L. A. Doughty, W. G. Cioffi, and A. Ayala. 2003. Differential effects of 
macrophage inflammatory chemokine-2 and keratinocyte-derived chemokine on 
hemorrhage-induced neutrophil priming for lung inflammation: assessment by adoptive 
cells transfer in mice. Shock 19: 358-365. 
131. Faith, M., A. Sukumaran, A. B. Pulimood, and M. Jacob. 2008. How reliable an indicator 
of inflammation is myeloperoxidase activity? Clinica chimica acta; international journal 
of clinical chemistry 396: 23-25. 
103 
 
132. Rouse, J., P. Cohen, S. Trigon, M. Morange, A. Alonso-Llamazares, D. Zamanillo, T. 
Hunt, and A. R. Nebreda. 1994. A novel kinase cascade triggered by stress and heat 
shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock 
proteins. Cell 78: 1027-1037. 
133. Freshney, N. W., L. Rawlinson, F. Guesdon, E. Jones, S. Cowley, J. Hsuan, and J. 
Saklatvala. 1994. Interleukin-1 activates a novel protein kinase cascade that results in the 
phosphorylation of Hsp27. Cell 78: 1039-1049. 
134. Han, J., J. D. Lee, L. Bibbs, and R. J. Ulevitch. 1994. A MAP kinase targeted by 
endotoxin and hyperosmolarity in mammalian cells. Science 265: 808-811. 
135. Galcheva-Gargova, Z., B. Derijard, I. H. Wu, and R. J. Davis. 1994. An osmosensing 
signal transduction pathway in mammalian cells. Science 265: 806-808. 
136. Liu, S., G. Feng, G. L. Wang, and G. J. Liu. 2008. p38MAPK inhibition attenuates LPS-
induced acute lung injury involvement of NF-kappaB pathway. European journal of 
pharmacology 584: 159-165. 
137. Mehta, D., and A. B. Malik. 2006. Signaling mechanisms regulating endothelial 
permeability. Physiol Rev 86: 279-367. 
138. Ong, E. S., X. P. Gao, N. Xu, D. Predescu, A. Rahman, M. T. Broman, D. H. Jho, and A. 
B. Malik. 2003. E. coli pneumonia induces CD18-independent airway neutrophil 
migration in the absence of increased lung vascular permeability. American journal of 
physiology. Lung cellular and molecular physiology 285: L879-888. 
139. Kubes, P., M. Suzuki, and D. N. Granger. 1990. Modulation of PAF-induced leukocyte 
adherence and increased microvascular permeability. The American journal of physiology 
259: G859-864. 
104 
 
140. Baluk, P., P. Bolton, A. Hirata, G. Thurston, and D. M. McDonald. 1998. Endothelial 
gaps and adherent leukocytes in allergen-induced early- and late-phase plasma leakage in 
rat airways. American Journal of Pathology 152: 1463-1476. 
141. Hurley, J. V. 1964. Acute Inflammation: The Effect of Concurrent Leucocytic 
Emigration and Increased Permeability on Particle Retention by the Vascular Wall. Br J 
Exp Pathol 45: 627-633. 
142. Aharonson-Raz, K., K. L. Lohmann, H. G. Townsend, F. Marques, and B. Singh. 2012. 
Pulmonary intravascular macrophages as proinflammatory cells in heaves, an asthma-like 
equine disease. American journal of physiology. Lung cellular and molecular physiology 
303: L189-198. 
143. Koller, B., M. Kappler, P. Latzin, A. Gaggar, M. Schreiner, S. Takyar, M. Kormann, M. 
Kabesch, D. Roos, M. Griese, and D. Hartl. 2008. TLR expression on neutrophils at the 
pulmonary site of infection: TLR1/TLR2-mediated up-regulation of TLR5 expression in 
cystic fibrosis lung disease. J Immunol 181: 2753-2763. 
144. Janardhan, K. S., M. McIsaac, J. Fowlie, A. Shrivastav, S. Caldwell, R. K. Sharma, and 
B. Singh. 2006. Toll like receptor-4 expression in lipopolysaccharide induced lung 
inflammation. Histology and histopathology 21: 687-696. 
145. Riedemann, N. C., and P. A. Ward. 2002. Oxidized lipid protects against sepsis. Nature 
medicine 8: 1084-1085. 
146. Peng, T., X. Lu, and Q. Feng. 2005. NADH oxidase signaling induces cyclooxygenase-2 
expression during lipopolysaccharide stimulation in cardiomyocytes. FASEB journal : 
official publication of the Federation of American Societies for Experimental Biology 19: 
293-295. 
105 
 
147. Hostetter, S. J. 2012. Neutrophil function in small animals. Vet Clin North Am Small 
Anim Pract 42: 157-171. 
148. Fialkow, L., Y. Wang, and G. P. Downey. 2007. Reactive oxygen and nitrogen species as 
signaling molecules regulating neutrophil function. Free radical biology & medicine 42: 
153-164. 
 
 
 
 
 
